{
    "headline": "The microeconomics of personalized medicine",
    "link": "https://www.mckinsey.com/industries/life-sciences/our-insights/the-microeconomics-of-personalized-medicine",
    "content": "<!DOCTYPE html><html dir=\"ltr\" lang=\"en\"><head><meta charset=\"utf-8\"><meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\"><meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\"><iframe src=\"javascript:void(0)\" title=\"\" role=\"presentation\" style=\"width: 0px; height: 0px; border: 0px; display: none;\"></iframe><script>var McKinsey = {\"ArticleTemplate\":\"Legacy\",\"DaysSinceCMSPublication\":\"607\",\"DisplayDate\":\"2/1/2010\",\"OriginalPublicationDate\":\"2/1/2010\",\"SitecoreId\":\"{1B13B0B4-89B5-4F5C-B948-EE5F5E9463CB}\",\"Title\":\"The microeconomics of personalized medicine\",\"ArticleType\":\"Article\",\"ContentType\":\"Article\",\"ServerNumber\":\"\",\"IsPageRestricted\":\"true\",\"UserID\":\"\",\"RegistrationDate\":\"\",\"LoginStatus\":\"logged_out\",\"JobTitle\":\"\",\"CompanyName\":\"\",\"blogTags\":null}; var pageMetaInformation = {\"CurrentLanguage\":\"en\",\"AlternateLanguages\":[{\"DisplayName\":\"English\",\"LanguageCode\":\"en\",\"Url\":\"/industries/life-sciences/our-insights/the-microeconomics-of-personalized-medicine\"}],\"NavigationLink\":\"industries\",\"ActiveItemId\":\"{BB8498AC-8CC4-4BFB-8832-53C76F3E61CF}\",\"OfficeCode\":\"\",\"MiniSiteId\":\"{CDBF3A89-AE60-459E-ACF8-786E31307534}\"};</script><link rel=\"icon\" href=\"/favicon.ico\"><link href=\"https://www.mckinsey.com/redesign/resources/css/styles-rc.css\" rel=\"stylesheet\"><link rel=\"manifest\" href=\"/manifest.json\"><link rel=\"dns-prefetch\" href=\"//cdn.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//st.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//rcom.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//cdn.cookielaw.org\"><link rel=\"preconnect\" href=\"//assets.adobedtm.com\"><link rel=\"preconnect\" href=\"//connect.facebook.net\"><link rel=\"preconnect\" href=\"//static.hotjar.com\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/bower/Bower-Bold.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/regular/McKinseySans-Regular.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/medium/McKinseySans-Medium.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/light/McKinseySans-Light.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/italic/McKinseySans-Italic.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/light-italic/McKinseySans-LightItalic.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/medium-italic/McKinseySans-MediumItalic.woff2\" type=\"font/woff2\" crossorigin=\"\"><meta name=\"apple-itunes-app\" content=\"app-id=674902075\"><link rel=\"apple-touch-icon\" sizes=\"57x57\" href=\"/next-static/images/mck-touch-icon-57x57.png\"><link rel=\"apple-touch-icon\" sizes=\"72x72\" href=\"/next-static/images/mck-touch-icon-72x72.png\"><link rel=\"apple-touch-icon\" sizes=\"114x114\" href=\"/next-static/images/mck-touch-icon-114x114.png\"><link rel=\"apple-touch-icon\" sizes=\"144x144\" href=\"/next-static/images/mck-touch-icon-144x144.png\"><link rel=\"apple-touch-icon\" sizes=\"152x152\" href=\"/next-static/images/mck-touch-icon-152x152.png\"><link rel=\"apple-touch-icon\" sizes=\"167x167\" href=\"/next-static/images/mck-touch-icon-167x167.png\"><link rel=\"apple-touch-icon\" sizes=\"180x180\" href=\"/next-static/images/mck-touch-icon-180x180.png\"><meta content=\"no-referrer-when-downgrade\" name=\"referrer\"><meta content=\"McKinsey &amp; Company\" property=\"og:site_name\" name=\"site_name\"><meta content=\"The microeconomics of personalized medicine\" property=\"og:title\" name=\"title\"><meta content=\"Personalized medicine promises to increase the quality of clinical care and, in some cases, to decrease health care costs. The biggest hurdles are economic, not scientific.\" property=\"og:description\" name=\"description\"><meta content=\"https://www.mckinsey.com/industries/life-sciences/our-insights/the-microeconomics-of-personalized-medicine\" name=\"url\" property=\"og:url\"><meta content=\"index,follow,all\" name=\"robots\"><meta content=\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/mipe10_frth.jpg\" property=\"og:image\" name=\"image\"><meta content=\"{1B13B0B4-89B5-4F5C-B948-EE5F5E9463CB}\" name=\"sid\"><link href=\"https://www.mckinsey.com/industries/life-sciences/our-insights/the-microeconomics-of-personalized-medicine\" rel=\"canonical\"><meta content=\"Life Sciences\" name=\"practice-name\"><meta content=\"N20\" name=\"practice-code\"><meta content=\"summary_large_image\" name=\"twitter:card\"><meta content=\"@mckinsey\" name=\"twitter:site\"><title>The microeconomics of personalized medicine | McKinsey</title><meta content=\"Insights &amp; Publications\" name=\"sections\"><meta content=\"The microeconomics of personalized medicine\" name=\"twitter:title\"><meta content=\"Personalized medicine promises to increase the quality of clinical care and, in some cases, to decrease health care costs. The biggest hurdles are economic, not scientific.\" name=\"twitter:description\"><meta content=\"Article\" property=\"contenttype\" name=\"contenttype\"><meta content=\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/mipe10_frth.jpg?mw=677&amp;car=42:25\" name=\"twitter:image\"><meta content=\"The microeconomics of personalized medicine\" name=\"twitter:image:alt\"><meta content=\"true\" name=\"mobileready\"><meta content=\"public\" name=\"accesslevel\"><meta content=\"false\" name=\"excludefromclientlink\"><meta content=\"article\" name=\"articletype\"><meta content=\"Jerel Davis | Philip Ma | Saum Sutaria\" name=\"authors-name\"><meta content=\"2010-02-01T00:00:00Z\" name=\"itemdate\"><meta content=\"Life Sciences | Article | February 1, 2010\" name=\"searchresults-tags\"><script type=\"application/ld+json\">{\"@context\":\"https://schema.org\",\"@type\":\"Article\",\"url\":\"https://www.mckinsey.com\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"McKinsey & Company\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https://www.mckinsey.com/~/media/Thumbnails/Mck_Logo\"}},\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https://www.mckinsey.com/industries/life-sciences/our-insights/the-microeconomics-of-personalized-medicine\"},\"datePublished\":\"2010-02-01T00:00:00Z\",\"dateCreated\":\"2012-05-10T04:15:54Z\",\"dateModified\":\"2010-02-01T00:00:00Z\",\"heading\":\"The microeconomics of personalized medicine\",\"image\":\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/mipe10_frth.jpg\",\"description\":\"Personalized medicine promises to increase the quality of clinical care and, in some cases, to decrease health care costs. The biggest hurdles are economic, not scientific.\",\"author\":[{\"@type\":\"Person\",\"name\":\"Jerel Davis\"},{\"@type\":\"Person\",\"name\":\"Philip Ma\"},{\"@type\":\"Person\",\"name\":\"Saumya Sutaria\",\"url\":\"https://www.mckinsey.com/our-people/sarun-charumilind\"}]}</script><meta charset=\"utf-8\"><meta name=\"next-head-count\" content=\"58\"><meta name=\"next-font-preconnect\"><script src=\"\" id=\"onetrust-wrapperchecker\" data-nscript=\"beforeInteractive\">function OptanonWrapperChecker() {}</script><link rel=\"preload\" href=\"/_next/static/css/2fad2c5744177bb8.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/2fad2c5744177bb8.css\" data-n-g=\"\"><link rel=\"preload\" href=\"/_next/static/css/dc5a0fd9c531d8ae.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/dc5a0fd9c531d8ae.css\" data-n-p=\"\"><link rel=\"preload\" href=\"/_next/static/css/529ed6e2fac958b2.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/529ed6e2fac958b2.css\"><link rel=\"preload\" href=\"/_next/static/css/cb9982a1c7acea8c.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/cb9982a1c7acea8c.css\"><link rel=\"preload\" href=\"/_next/static/css/72fc56b1fbe032aa.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/72fc56b1fbe032aa.css\"><link rel=\"preload\" href=\"/_next/static/css/5e45d445fc213154.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/5e45d445fc213154.css\"><noscript data-n-css=\"\"></noscript><script defer=\"\" nomodule=\"\" src=\"/_next/static/chunks/polyfills-5cd94c89d3acac5f.js\"></script><script src=\"https://cdn.cookielaw.org/scripttemplates/otSDKStub.js\" data-document-language=\"true\" type=\"text/javascript\" data-domain-script=\"915b5091-0d7e-44d2-a8c4-cf08267e52fe\" defer=\"\" data-nscript=\"beforeInteractive\"></script><script defer=\"\" src=\"/_next/static/chunks/281.674cd4210cb46873.js\"></script><script defer=\"\" src=\"/_next/static/chunks/3769.eb77385153f1a4b1.js\"></script><script defer=\"\" src=\"/_next/static/chunks/6731.9bccca8a7edb0704.js\"></script><script defer=\"\" src=\"/_next/static/chunks/8391.a64dec5b7b976b97.js\"></script><script src=\"/_next/static/chunks/webpack.47afe4b83145c95f.js\" defer=\"\"></script><script src=\"/_next/static/chunks/framework.62bbe2ca94854a85.js\" defer=\"\"></script><script src=\"/_next/static/chunks/main.51e10588adc949ca.js\" defer=\"\"></script><script src=\"/_next/static/chunks/pages/_app.e3dd57df2dc16789.js\" defer=\"\"></script><script src=\"/_next/static/chunks/3b1baa31.cd6cdac6158774d8.js\" defer=\"\"></script><script src=\"/_next/static/chunks/7d0bf13e.8f3383787afb45af.js\" defer=\"\"></script><script src=\"/_next/static/chunks/1354.c34ddc4bd7c986c8.js\" defer=\"\"></script><script src=\"/_next/static/chunks/408.9bf4e4647a127fd0.js\" defer=\"\"></script><script src=\"/_next/static/chunks/pages/%5B%5B...path%5D%5D.99501948ed14e00a.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_buildManifest.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_ssgManifest.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_middlewareManifest.js\" defer=\"\"></script>\n<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push([\"addVar\",{\"rua.upush\":\"false\",\"rua.cpush\":\"false\",\"rua.upre\":\"false\",\"rua.cpre\":\"false\",\"rua.uprl\":\"false\",\"rua.cprl\":\"false\",\"rua.cprf\":\"false\",\"rua.trans\":\"SJ-b7ca1abb-ecba-4149-9919-3f315fab5f35\",\"rua.cook\":\"true\",\"rua.ims\":\"false\",\"rua.ufprl\":\"false\",\"rua.cfprl\":\"false\",\"rua.isuxp\":\"false\",\"rua.texp\":\"norulematch\",\"rua.ceh\":\"false\",\"rua.ueh\":\"false\",\"rua.ieh.st\":\"0\"}]);</script>\n                              <script>!function(a){var e=\"https://s.go-mpulse.net/boomerang/\",t=\"addEventListener\";if(\"False\"==\"True\")a.BOOMR_config=a.BOOMR_config||{},a.BOOMR_config.PageParams=a.BOOMR_config.PageParams||{},a.BOOMR_config.PageParams.pci=!0,e=\"https://s2.go-mpulse.net/boomerang/\";if(window.BOOMR_API_key=\"TURRK-8ADJT-WDUC5-TC32E-KV9ND\",function(){function n(e){a.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!a.BOOMR||!a.BOOMR.version&&!a.BOOMR.snippetExecuted){a.BOOMR=a.BOOMR||{},a.BOOMR.snippetExecuted=!0;var i,_,o,r=document.createElement(\"iframe\");if(a[t])a[t](\"load\",n,!1);else if(a.attachEvent)a.attachEvent(\"onload\",n);r.src=\"javascript:void(0)\",r.title=\"\",r.role=\"presentation\",(r.frameElement||r).style.cssText=\"width:0;height:0;border:0;display:none;\",o=document.getElementsByTagName(\"script\")[0],o.parentNode.insertBefore(r,o);try{_=r.contentWindow.document}catch(O){i=document.domain,r.src=\"javascript:var d=document.open();d.domain='\"+i+\"';void(0);\",_=r.contentWindow.document}_.open()._l=function(){var a=this.createElement(\"script\");if(i)this.domain=i;a.id=\"boomr-if-as\",a.src=e+\"TURRK-8ADJT-WDUC5-TC32E-KV9ND\",BOOMR_lstart=(new Date).getTime(),this.body.appendChild(a)},_.write(\"<bo\"+'dy onload=\"document._l();\">'),_.close()}}(),\"\".length>0)if(a&&\"performance\"in a&&a.performance&&\"function\"==typeof a.performance.setResourceTimingBufferSize)a.performance.setResourceTimingBufferSize();!function(){if(BOOMR=a.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var e=\"false\"==\"true\"?1:0,t=\"cookiepresent\",n=\"ajsxrwycc6kamzy2onbq-f-3d29373ec-clientnsv4-s.akamaihd.net\",i=\"false\"==\"true\"?2:1,_={\"ak.v\":\"39\",\"ak.cp\":\"19387\",\"ak.ai\":parseInt(\"285213\",10),\"ak.ol\":\"0\",\"ak.cr\":14,\"ak.ipv\":4,\"ak.proto\":\"h2\",\"ak.rid\":\"47e14d\",\"ak.r\":49473,\"ak.a2\":e,\"ak.m\":\"a\",\"ak.n\":\"essl\",\"ak.bpcip\":\"2.101.120.0\",\"ak.cport\":63914,\"ak.gh\":\"2.21.6.28\",\"ak.quicv\":\"\",\"ak.tlsv\":\"tls1.3\",\"ak.0rtt\":\"\",\"ak.0rtt.ed\":\"\",\"ak.csrc\":\"-\",\"ak.acc\":\"\",\"ak.t\":\"1729786691\",\"ak.ak\":\"hOBiQwZUYzCg5VSAfCLimQ==SkjOCeRLAem61DscH/20oYOkI7j6xFPo1q0NU/wEG8kBs+a3ICGqDAbsnW/ZrgBGLDtzCs+LZo+mgS/NTF3ZTj6CuEtlhwhQxto82fCRdKeg1Ja3RBV8Raq7MQSPGJjyRQhYgOgwafvroZK96Od4NJqR39xovmxu/IPEIs4Jd85FnPFSgGli/u/JtE1WQxLX4p+56HekQ56yxi0SX6yeqoRFybKUme9yF+I7noCIXtsUsQeK/VZ7lG5qNgB/XCIPvPB1utX+/BAaz3wwm7v42tWfF9FWWs7m96zn/tOazRsYeQ6EYUPtaAhroF/LRrpLNTne5ujhsuqMtteIlM/ZFjBtnMIz0e4gsNOiWQPhOKotOp31LuvUPyxPx0cO07Yo2zP8DYEDyHl+x6KPhkuK07cTmy971Rj7LFpuK9IPBwA=\",\"ak.pv\":\"570\",\"ak.dpoabenc\":\"\",\"ak.tf\":i};if(\"\"!==t)_[\"ak.ruds\"]=t;var o={i:!1,av:function(e){var t=\"http.initiator\";if(e&&(!e[t]||\"spa_hard\"===e[t]))_[\"ak.feo\"]=void 0!==a.aFeoApplied?1:0,BOOMR.addVar(_)},rv:function(){var a=[\"ak.bpcip\",\"ak.cport\",\"ak.cr\",\"ak.csrc\",\"ak.gh\",\"ak.ipv\",\"ak.m\",\"ak.n\",\"ak.ol\",\"ak.proto\",\"ak.quicv\",\"ak.tlsv\",\"ak.0rtt\",\"ak.0rtt.ed\",\"ak.r\",\"ak.acc\",\"ak.t\",\"ak.tf\"];BOOMR.removeVar(a)}};BOOMR.plugins.AK={akVars:_,akDNSPreFetchDomain:n,init:function(){if(!o.i){var a=BOOMR.subscribe;a(\"before_beacon\",o.av,null,null),a(\"onbeacon\",o.rv,null,null),o.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><style type=\"text/css\">.mdc-c-button___U4iY2_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border:var(--mdc-size-border-width-1) solid #0000;border-radius:0;color:var(--text-color-default);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}.mdc-c-button___U4iY2_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--primary___Ed-lT_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;background-color:var(--button-primary-background);border:var(--mdc-size-border-width-1) solid #0000;border-radius:0;color:var(--button-primary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--primary___Ed-lT_990311c:hover{background-color:var(--button-primary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--primary___Ed-lT_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--primary___Ed-lT_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text)}.mdc-c-button--primary___Ed-lT_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text);color:var(--button-primary-background)}@media (hover:hover){.mdc-c-button--primary___Ed-lT_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text-hover)}.mdc-c-button--primary___Ed-lT_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text-hover);color:var(--button-primary-background-hover)}}.mdc-c-button--primary___Ed-lT_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text)}.mdc-c-button--primary___Ed-lT_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text);color:var(--button-primary-background)}.mdc-c-button--secondary___Boipq_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;background-color:var(--button-primary-background);background-color:var(--button-secondary-background);border:var(--mdc-size-border-width-1) solid var(--button-secondary-border);border-radius:0;color:var(--button-primary-text);color:var(--button-secondary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--secondary___Boipq_990311c:hover{background-color:var(--button-primary-background-hover);background-color:var(--button-secondary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);border:var(--mdc-size-border-width-1) solid var(--button-secondary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);color:var(--button-secondary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--secondary___Boipq_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--secondary___Boipq_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text);line-height:1}.mdc-c-button--secondary___Boipq_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text);color:var(--mdc-color-neutral-white)}@media (hover:hover){.mdc-c-button--secondary___Boipq_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text-hover)}.mdc-c-button--secondary___Boipq_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text-hover);color:var(--button-secondary-background-hover)}}.mdc-c-button--secondary___Boipq_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text)}.mdc-c-button--secondary___Boipq_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text);color:var(--button-secondary-icon-focus)}.mdc-c-button--tertiary___zPM6q_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:var(--button-primary-background);background-color:initial;border:var(--mdc-size-border-width-1) solid var(--button-tertiary-border);border-radius:0;color:var(--button-primary-text);color:var(--button-tertiary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--tertiary___zPM6q_990311c:hover{background-color:var(--button-primary-background-hover);background-color:var(--button-tertiary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);border:var(--mdc-size-border-width-1) solid var(--button-tertiary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);color:var(--button-tertiary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--tertiary___zPM6q_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--tertiary___zPM6q_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text)}.mdc-c-button--tertiary___zPM6q_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text);color:var(--button-tertiary-text-hover)}@media (hover:hover){.mdc-c-button--tertiary___zPM6q_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text-hover)}.mdc-c-button--tertiary___zPM6q_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text-hover);color:var(--button-tertiary-text)}}.mdc-c-button--tertiary___zPM6q_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text)}.mdc-c-button--tertiary___zPM6q_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text);color:var(--button-tertiary-text-hover)}.mdc-c-button--minimal___Uzgaz_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-primary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal___Uzgaz_990311c:hover{border-bottom-color:var(--button-minimal-primary)}}.mdc-c-button--minimal___Uzgaz_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal___Uzgaz_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal___Uzgaz_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--minimal-secondary___W0Qrc_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-secondary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal-secondary___W0Qrc_990311c:hover{border-bottom-color:var(--button-minimal-secondary)}}.mdc-c-button--minimal-secondary___W0Qrc_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal-secondary___W0Qrc_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal-secondary___W0Qrc_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--minimal-tertiary___YwyAF_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-tertiary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal-tertiary___YwyAF_990311c:hover{border-bottom-color:var(--button-minimal-tertiary-hover);color:var(--button-minimal-tertiary-hover)}}.mdc-c-button--minimal-tertiary___YwyAF_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal-tertiary___YwyAF_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal-tertiary___YwyAF_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--size-large___jwpUy_990311c{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28);min-height:var(--mdc-size-spacing-48);padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-24)}.mdc-c-button--size-small___uvMIB_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);min-height:var(--mdc-size-spacing-32);min-width:var(--mdc-size-spacing-72);padding:var(--mdc-size-spacing-4) var(--mdc-size-spacing-16)}.mdc-c-button--btn-compact___P-iHa_990311c{min-width:auto}.mdc-c-button--disabled___Xbyp5_990311c{border:none!important;cursor:not-allowed}.mdc-c-button--disabled___Xbyp5_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c:hover{border:none!important;box-shadow:none!important;outline:none!important;transform:none!important}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--primary___Ed-lT_990311c{background-color:var(--button-primary-disabled-background);color:var(--button-disabled-text)}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c{background-color:var(--button-secondary-disabled-background);border:var(--mdc-size-border-width-1) solid var(--button-secondary-disabled-border)!important;color:var(--button-disabled-text)}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:hover,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:hover{border:var(--mdc-size-border-width-1) solid var(--button-secondary-disabled-border)!important}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal-secondary___W0Qrc_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal-tertiary___YwyAF_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal___Uzgaz_990311c{color:var(--button-minimal-disabled)}</style><style type=\"text/css\">.mdc-c-link-cta___NBQVi_990311c,.mdc-c-link-icon___SEKyg_990311c,.mdc-c-link-inline___7DRrt_990311c,.mdc-c-link___lBbY1_990311c{align-items:center;color:currentcolor;display:inline-flex;gap:var(--mdc-size-spacing-8)}.mdc-c-link-cta___NBQVi_990311c:focus-visible,.mdc-c-link-icon___SEKyg_990311c:focus-visible,.mdc-c-link-inline___7DRrt_990311c:focus-visible,.mdc-c-link___lBbY1_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--link-color-selected);outline-offset:var(--mdc-size-border-width-4)}.mdc-c-link___lBbY1_990311c{color:var(--link-color-default);text-decoration:none}.mdc-c-link___lBbY1_990311c:focus .mdc-c-link__label___Pfqtd_990311c,.mdc-c-link___lBbY1_990311c:hover .mdc-c-link__label___Pfqtd_990311c{text-decoration-line:underline;text-decoration-thickness:calc(var(--mdc-size-spacing-4)/2);text-underline-offset:calc(var(--mdc-size-spacing-4)/2)}.mdc-c-link--secondary___TSFam_990311c{color:var(--link-color-secondary-default)}.mdc-c-link-inline___7DRrt_990311c{border-bottom:2px solid var(--link-inline-default-border-color);color:currentcolor;line-height:1;padding-left:calc(var(--mdc-size-spacing-4)/2);padding-right:calc(var(--mdc-size-spacing-4)/2);text-decoration:none;transition:.12s linear;transition-property:background-color,color}.mdc-c-link-inline___7DRrt_990311c:hover{background-color:var(--link-inline-default-background-hover-color);border-color:var(--link-inline-default-border-hover-color);color:var(--link-inline-default-hover-color);text-decoration:none}.mdc-c-link-inline--secondary___YKoOK_990311c{border-bottom-color:initial}.mdc-c-link-inline--secondary___YKoOK_990311c:hover{background-color:var(--link-inline-secondary-background-hover-color);border-bottom-color:var(--link-inline-secondary-background-hover-color);color:var(--link-inline-secondary-hover-color)}.mdc-c-link-cta___NBQVi_990311c{color:var(--link-color-text-default);display:inline-block;font-weight:var(--mdc-font-weight-medium)}.mdc-c-link-cta___NBQVi_990311c span[class$=icon]{padding-left:var(--mdc-size-spacing-8);padding-right:var(--mdc-size-spacing-16);transition:padding .4s ease-in-out;vertical-align:initial}.mdc-c-link-cta___NBQVi_990311c span[class$=icon]:before{color:var(--link-cta-icon-color)}.mdc-c-link-cta___NBQVi_990311c:active,.mdc-c-link-cta___NBQVi_990311c:focus,.mdc-c-link-cta___NBQVi_990311c:hover{color:var(--link-color-text-default-hover)}.mdc-c-link-cta___NBQVi_990311c:active span[class$=icon],.mdc-c-link-cta___NBQVi_990311c:focus span[class$=icon],.mdc-c-link-cta___NBQVi_990311c:hover span[class$=icon]{padding-left:var(--mdc-size-spacing-24);padding-right:0}.mdc-c-link-cta--size-large___udJoH_990311c{font-size:var(--mdc-size-font-20);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-32)}@media (min-width:1180px){.mdc-c-link-cta--size-large___udJoH_990311c{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}.mdc-c-link-cta--size-large___udJoH_990311c span[class$=icon]{padding-left:var(--mdc-size-spacing-16);padding-right:var(--mdc-size-spacing-32);transition:padding .4s ease-in-out;vertical-align:initial}.mdc-c-link-cta--size-large___udJoH_990311c span[class$=icon]:before{color:var(--link-cta-icon-color)}.mdc-c-link-cta--size-large___udJoH_990311c:active,.mdc-c-link-cta--size-large___udJoH_990311c:focus,.mdc-c-link-cta--size-large___udJoH_990311c:hover{color:var(--link-color-text-default-hover)}.mdc-c-link-cta--size-large___udJoH_990311c:active span[class$=icon],.mdc-c-link-cta--size-large___udJoH_990311c:focus span[class$=icon],.mdc-c-link-cta--size-large___udJoH_990311c:hover span[class$=icon]{padding-left:var(--mdc-size-spacing-48);padding-right:0}}.mdc-c-link-icon___SEKyg_990311c{color:var(--link-icon-color)}.mdc-c-link-icon___SEKyg_990311c:focus,.mdc-c-link-icon___SEKyg_990311c:hover{color:var(--link-icon-hover-color)}.mdc-c-link-icon___SEKyg_990311c:focus [class^=\"mdc-c-icon--radial::before\"],.mdc-c-link-icon___SEKyg_990311c:hover [class^=\"mdc-c-icon--radial::before\"]{background-color:var(--link-icon-hover-color);color:var(--link-icon-radial-hover-color)}.mdc-c-link-icon___SEKyg_990311c:focus .mdc-c-link__label___Pfqtd_990311c,.mdc-c-link-icon___SEKyg_990311c:hover .mdc-c-link__label___Pfqtd_990311c{text-decoration-line:underline}.mdc-c-link-heading___Zggl8_990311c{color:var(--link-heading-color);font-weight:var(--mdc-font-weight-medium)}.mdc-c-link-heading___Zggl8_990311c:focus,.mdc-c-link-heading___Zggl8_990311c:hover{color:var(--link-heading-hover-color);text-decoration-line:underline;text-decoration-thickness:.07em;text-underline-offset:var(--mdc-size-spacing-4)}.mdc-c-link-heading___Zggl8_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--link-color-selected);outline-offset:var(--mdc-size-border-width-4)}.mdc-c-link-heading--with-icon___ssPll_990311c{display:inline;padding-right:var(--mdc-size-spacing-8)}</style><style type=\"text/css\">.mdc-c-toast__wrapper--active___FhXwN_990311c{z-index:9999}.mdc-c-toast__wrapper--active___FhXwN_990311c>*{pointer-events:auto}.mdc-c-toast__content___aJ0xH_990311c{background:var(--mdc-color-neutral-white);box-shadow:0 7px 14px 0 #0003;max-width:min(100%,var(--mdc-breakpoint-md));padding:var(--mdc-size-spacing-16);pointer-events:auto;will-change:transform}.mdc-c-toast__alert-container___bP-MJ_990311c{padding:0!important}.mdc-c-toast__alert___xdRqn_990311c{background-color:var(--mdc-color-neutral-white)!important;border-color:var(--mdc-color-neutral-gray-06)!important;max-width:min(100%,var(--mdc-breakpoint-lg))}.mdc-c-toast__alert___xdRqn_990311c [data-component=mdc-c-icon]:focus:before,.mdc-c-toast__alert___xdRqn_990311c [data-component=mdc-c-icon]:hover:before{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-toast__message___r6An3_990311c{color:inherit;display:flex;flex:1 1 auto;justify-content:center;white-space:pre-line}</style><style type=\"text/css\">.mdc-c-module-wrapper--full-page___3XZ1n_990311c{align-items:center;display:flex;height:100dvh;justify-content:center;left:0;margin:0!important;padding:0!important;top:0;width:100vw}.mdc-c-module-wrapper--full-page___3XZ1n_990311c img:first-of-type,.mdc-c-module-wrapper--full-page___3XZ1n_990311c video:first-of-type,.mdc-c-module-wrapper--full-page___3XZ1n_990311c>.image___T6Mcc_990311c,.mdc-c-module-wrapper--full-page___3XZ1n_990311c>.mdc-c-bg-image___z77CN_990311c{height:100%;object-fit:cover;width:100%}.story-wrapper{padding:0!important}</style><style type=\"text/css\">:root .mdc-c-icon-svg___68K-O_990311c,[data-module-theme=light] .mdc-c-icon-svg___68K-O_990311c{--icon-svg-stroke-color:currentcolor;--icon-svg-fill-color:none}[data-module-theme=dark] .mdc-c-icon-svg___68K-O_990311c{--icon-svg-stroke-color:var(--mdc-color-neutral-white);--icon-svg-fill-color:none}.mdc-c-icon-svg___68K-O_990311c{display:inline-flex}.mdc-c-icon-svg___68K-O_990311c svg{fill:var(--icon-svg-fill-color)}</style><style type=\"text/css\">:root .mdc-c-icon___oi7ef_990311c,[data-module-theme=light] .mdc-c-icon___oi7ef_990311c{--icon-radial-color:var(--mdc-color-neutral-white);--icon-radial-background-color:var(--mdc-color-neutral-black);--icon-radial-background-color-hover:var(--mdc-color-palette-electric-blue)}[data-module-theme=dark] .mdc-c-icon___oi7ef_990311c{--icon-radial-color:var(--mdc-color-neutral-black);--icon-radial-background-color:var(--mdc-color-neutral-white);--icon-radial-background-color-hover:var(--mdc-color-palette-cyan)}:root .mdc-c-icon--secondary___dSlsG_990311c,[data-module-theme=light] .mdc-c-icon--secondary___dSlsG_990311c{--icon-radial-color:var(--mdc-color-neutral-black);--icon-radial-background-color:unset;--icon-radial-background-color-hover:var(--mdc-color-neutral-gray-06)}[data-module-theme=dark] .mdc-c-icon--secondary___dSlsG_990311c{--icon-radial-color:var(--mdc-color-neutral-white);--icon-radial-background-color:unset;--icon-radial-background-color-hover:var(--mdc-color-palette-cyan)}.mdc-c-icon___oi7ef_990311c{display:inline;line-height:inherit;vertical-align:middle}.mdc-c-icon___oi7ef_990311c:before{color:currentcolor;vertical-align:middle}.mdc-c-icon--outline___MU0j1_990311c:before,.mdc-c-icon--radial___y3csX_990311c:before,.mdc-c-icon-default___0TDAM_990311c:before{font-size:inherit;position:relative}.mdc-c-icon--outline___MU0j1_990311c:hover span,.mdc-c-icon--radial___y3csX_990311c:hover span,.mdc-c-icon-default___0TDAM_990311c:hover span{border-color:inherit;color:inherit}.mdc-c-icon--default___f-hQM_990311c:before{display:block}.mdc-c-icon--outline___MU0j1_990311c:before,.mdc-c-icon--radial___y3csX_990311c:before{align-items:center;border-radius:50%;display:inline-flex;flex-shrink:0;font-size:.5em;height:var(--mdc-size-icon-16);justify-content:center;width:var(--mdc-size-icon-16)}a .mdc-c-icon--outline___MU0j1_990311c:only-child:before,a .mdc-c-icon--radial___y3csX_990311c:only-child:before{transition:.12s linear;transition-property:all}a .mdc-c-icon--outline___MU0j1_990311c:hover:only-child:before,a .mdc-c-icon--radial___y3csX_990311c:hover:only-child:before{box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--icon-radial-background-color);color:var(--icon-radial-color)}a .mdc-c-icon--radial___y3csX_990311c:hover:before,button .mdc-c-icon--radial___y3csX_990311c:hover:before{background-color:var(--icon-radial-background-color-hover)}a:focus .mdc-c-icon--radial___y3csX_990311c:before,a:hover .mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--link-icon-hover-color);color:var(--link-icon-radial-hover-color)}.mdc-c-icon--success___2CfF7_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--mdc-color-status-dark-green);color:var(--mdc-color-neutral-white)}.mdc-c-icon--error___3PoQX_990311c:before{color:var(--mdc-color-status-dark-red)}.mdc-c-icon--error___3PoQX_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--mdc-color-status-dark-red);color:var(--mdc-color-neutral-white)}.mdc-c-icon--info___fsGGT_990311c:before{color:var(--mdc-color-palette-electric-blue)}.mdc-c-icon--warning___iP6zl_990311c:before{color:var(--mdc-color-status-dark-yellow)}.mdc-c-icon--active___4KblW_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--icon-radial-background-color-hover)}.mdc-c-icon--active___4KblW_990311c.mdc-c-icon--outline___MU0j1_990311c:before{background-color:unset;border:var(--mdc-size-border-width-1) solid var(--icon-radial-background-color-hover);color:var(--icon-radial-background-color-hover)}a .mdc-c-icon--secondary___dSlsG_990311c.mdc-c-icon--radial___y3csX_990311c:only-child:before{transition:none}a .mdc-c-icon--secondary___dSlsG_990311c.mdc-c-icon--radial___y3csX_990311c:hover:only-child:before{box-shadow:none;transform:none}.mdc-c-icon--outline___MU0j1_990311c:before{border:var(--mdc-size-border-width-1) solid;border-radius:50%;font-size:.5em}.mdc-c-icon--size-xs___g8-q5_990311c{font-size:var(--mdc-size-icon-10)}.mdc-c-icon--size-xs___g8-q5_990311c:before{height:var(--mdc-size-icon-10);width:var(--mdc-size-icon-10)}.mdc-c-icon--size-sm___2FLYH_990311c{font-size:var(--mdc-size-icon-12)}.mdc-c-icon--size-sm___2FLYH_990311c:before{height:var(--mdc-size-icon-12);width:var(--mdc-size-icon-12)}.mdc-c-icon--size-md___yi5fA_990311c{font-size:var(--mdc-size-icon-16)}.mdc-c-icon--size-md___yi5fA_990311c:before{height:var(--mdc-size-icon-16);width:var(--mdc-size-icon-16)}.mdc-c-icon--size-lg___5rPck_990311c{font-size:var(--mdc-size-icon-24)}.mdc-c-icon--size-lg___5rPck_990311c:before{height:var(--mdc-size-icon-24);width:var(--mdc-size-icon-24)}.mdc-c-icon--size-xl___3BEee_990311c{font-size:var(--mdc-size-icon-32)}.mdc-c-icon--size-xl___3BEee_990311c:before{height:var(--mdc-size-icon-32);width:var(--mdc-size-icon-32)}.mdc-c-icon--size-xxl___cL3ZT_990311c{font-size:var(--mdc-size-icon-40)}.mdc-c-icon--size-xxl___cL3ZT_990311c:before{height:var(--mdc-size-icon-40);width:var(--mdc-size-icon-40)}.mdc-c-icon--align-right___94-AR_990311c{order:2}.mdc-c-content-icon--size-sm___2acYB_990311c,.mdc-c-content-icon--size-xs___hPSY1_990311c{font-size:var(--mdc-size-font-16)}.mdc-c-content-icon--size-md___U5-qz_990311c{font-size:var(--mdc-size-font-24)}.mdc-c-content-icon--size-lg___ALqld_990311c{font-size:var(--mdc-size-font-28)}.mdc-c-content-icon--size-xl___4LKWE_990311c{font-size:var(--mdc-size-font-36)}.mdc-c-content-icon--size-xxl___PB38p_990311c{font-size:var(--mdc-size-font-44)}</style><style type=\"text/css\">.mdc-c-heading___0fM1W_990311c{text-shadow:var(--text-shadow)}.mdc-c-heading--title___5qyOB_990311c{font-family:var(--mdc-font-family-default-primary);font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-medium);letter-spacing:.075rem;line-height:var(--mdc-size-line-height-24);text-transform:uppercase}.mdc-c-heading--title___5qyOB_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--border___K8dj3_990311c{border-top:var(--mdc-size-border-width-1) solid;padding-top:var(--mdc-size-spacing-24)}.mdc-c-heading__icon___TbFKK_990311c{color:var(--link-cta-icon-color);position:absolute}</style><style type=\"text/css\">.mdc-c-description___SrnQP_990311c{text-shadow:var(--text-shadow)}.mdc-c-description___SrnQP_990311c>p:last-child{margin-bottom:0}</style><style type=\"text/css\">.mdc-c-accordion__items___yF0jA_990311c{border-bottom:var(--mdc-size-border-width-1) solid;border-top:var(--mdc-size-border-width-1) solid}.mdc-c-accordion__items--border-0___elAT7_990311c{border:none}.mdc-c-accordion__item___TaDQ0_990311c{word-break:break-word}.mdc-c-accordion__item___TaDQ0_990311c:not(:last-child){border-bottom:var(--mdc-size-border-width-1) solid}.mdc-c-accordion__title-wrapper___ujaRh_990311c{display:block!important;position:relative;text-align:inherit!important;width:100%}.mdc-c-accordion__title-wrapper___ujaRh_990311c:hover div{color:var(--button-minimal-primary)}.mdc-c-accordion__title___S2Csf_990311c{border-bottom:0;display:block;padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-48) var(--mdc-size-spacing-16) 0}.mdc-c-accordion__icon___MnUrM_990311c{position:absolute;right:var(--mdc-size-spacing-16);top:50%;transform:translateY(-50%);width:-webkit-max-content;width:max-content}.mdc-c-accordion__content-wrapper___WBkbu_990311c{padding-bottom:var(--mdc-size-spacing-16)}</style><style type=\"text/css\">.mdc-c-content-block___7p6Lu_990311c{grid-gap:var(--mdc-size-spacing-16);display:grid}.mdc-c-content-block--size-xxl___N8MW3_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-76);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-92)}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-44);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-52)}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-md___ZNL6I_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-md___ZNL6I_990311c [class^=mdc-c-heading]{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}.mdc-c-content-block--size-sm___8ZwhU_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24)}.mdc-c-content-block--size-sm___8ZwhU_990311c [class^=mdc-c-heading]{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--align-center___KRLtu_990311c{text-align:center}.mdc-c-content-block--align-center___KRLtu_990311c [class^=mdc-c-link-container]{justify-content:center;justify-items:center}.mdc-c-content-block--align-right___yCJP2_990311c{text-align:right}.mdc-c-content-block--align-right___yCJP2_990311c [class^=mdc-c-link-container]{justify-content:right;justify-items:right}</style><style type=\"text/css\">.mdc-c-link-container___xefGu_990311c{grid-gap:var(--mdc-size-spacing-16);align-items:flex-start;display:flex;flex-flow:column wrap}.mdc-c-link-container--display-column___X0HDD_990311c{align-items:center!important;flex-flow:row wrap;justify-content:flex-start}.mdc-c-link-container--align-center___ar3mu_990311c{align-items:center;justify-content:center}.mdc-c-link-container--align-right___6XjJx_990311c{align-items:flex-end;justify-content:flex-end}.mdc-c-link-container--display-row___LYWqK_990311c [class^=mdc-c-button]{align-self:stretch;max-width:100%}</style><style type=\"text/css\">.mdc-c-avatar___kVSTP_990311c{align-items:center;display:inline-flex;height:var(--mdc-avatar-size);justify-content:center;width:var(--mdc-avatar-size)}.mdc-c-avatar___kVSTP_990311c a{align-items:center;border-radius:inherit;color:var(--mdc-color-neutral-white);display:flex;height:100%;justify-content:center;overflow:hidden;width:100%}.mdc-c-avatar__hide___rnSnd_990311c{display:none}.mdc-c-avatar___kVSTP_990311c img{border-radius:inherit;height:inherit;width:inherit}.mdc-c-avatar--image___levct_990311c{background-color:var(--mdc-color-neutral-gray-04);border-radius:50%;display:inline-block}.mdc-c-avatar--image-placeholder___BX3C4_990311c{background-image:url(\"data:image/svg+xml;charset=utf-8,%3Csvg width='62' height='62' xmlns='http://www.w3.org/2000/svg'%3E%3Cdefs%3E%3Cfilter id='a'%3E%3CfeColorMatrix in='SourceGraphic' values='0 0 0 0 0.701961 0 0 0 0 0.701961 0 0 0 0 0.701961 0 0 0 1.000000 0'/%3E%3C/filter%3E%3C/defs%3E%3Cg filter='url(%23a)' transform='translate(-1 -1)' fill='%23B3B3B3' fill-rule='evenodd'%3E%3Cpath d='M32 1C14.906 1 1 14.907 1 32s13.906 31 31 31 31-13.907 31-31S49.094 1 32 1ZM20 28c0-6.617 5.383-12 12-12s12 5.383 12 12v3c0 6.617-5.383 12-12 12s-12-5.383-12-12v-3Zm12 33a28.847 28.847 0 0 1-17.789-6.122C17.082 49.99 22.26 47 28 47h8c5.733 0 10.911 2.99 13.788 7.879A28.845 28.845 0 0 1 32 61Z' fill='%23000'/%3E%3C/g%3E%3C/svg%3E\");background-repeat:no-repeat;background-size:contain}.mdc-c-avatar--text___Z2T5E_990311c{align-items:center;background-color:var(--mdc-color-palette-deep-blue);border-radius:50%;color:var(--mdc-color-neutral-white);display:inline-flex;font-weight:var(--mdc-font-weight-regular);justify-content:center}</style><style type=\"text/css\">.mdc-c-header__eyebrow___PZMpI_990311c{display:inline-block;font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);margin-bottom:var(--mdc-size-spacing-8)}.mdc-c-header__block___i1Lg-_990311c{grid-gap:var(--mdc-size-spacing-16);display:grid}</style><style type=\"text/css\">.mdc-c-bg-image___GJdv1_990311c{background-size:cover;min-height:100%}.mdc-c-bg-image--opaque-bg___CauU1_990311c{background-color:var(--mdc-color-neutral-black);bottom:0;left:0;position:absolute;right:0;top:0}</style><style type=\"text/css\">.mdc-c-tooltip___iYQYf_990311c{max-width:90%;min-width:160px;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);position:absolute;text-align:center}@media (min-width:768px){.mdc-c-tooltip___iYQYf_990311c{max-width:500px}}.mdc-c-tooltip--min-width-auto___Na7Bp_990311c{min-width:auto}.mdc-c-tooltip__arrow___BvUKx_990311c{position:absolute;width:15px}.mdc-c-tooltip__arrow--static___tBroH_990311c{bottom:-14px;left:50%;transform:translateX(-50%)}.mdc-c-tooltip--light___3HIZT_990311c{background-color:var(--mdc-color-neutral-white)}.mdc-c-tooltip--light___3HIZT_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-neutral-white)}.mdc-c-tooltip--semi-light___nUvVM_990311c{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-tooltip--semi-light___nUvVM_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-neutral-gray-06)}.mdc-c-tooltip--dark___EVQsg_990311c{background-color:var(--mdc-color-palette-deep-blue)}.mdc-c-tooltip--dark___EVQsg_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-palette-deep-blue)}.mdc-c-tooltip--elevated___KfVi2_990311c{box-shadow:0 7px 14px 0 #0003}</style><style type=\"text/css\">.mdc-c-brand-lines___HsR8E_990311c{height:0;width:0}.mdc-c-brand-lines__line___tr8-f_990311c{background-color:var(--mdc-color-palette-electric-blue);position:absolute}.mdc-c-brand-lines__line--left___tRtEV_990311c{left:0}.mdc-c-brand-lines__line--right___GLoBF_990311c{right:0}.mdc-c-brand-lines__line--top___4jrrn_990311c{top:0}.mdc-c-brand-lines__line--bottom___P7RVL_990311c{bottom:0}.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:20px;width:100%}@media (min-width:768px){.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:25px}}@media (min-width:1180px){.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:30px}}.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{height:100%;width:20px}@media (min-width:768px){.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{width:25px}}@media (min-width:1180px){.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{width:30px}}.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-20px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-20px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-20px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-20px}@media (min-width:768px){.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-25px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-25px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-25px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-30px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-30px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-30px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-30px}}.mdc-c-brand-lines__offset-filler___xRGlR_990311c{background-color:var(--mdc-color-palette-electric-blue);height:20px;position:absolute;width:20px}@media (min-width:768px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{height:25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{height:30px}}@media (min-width:768px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{width:25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{width:30px}}.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-20px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-20px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-20px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-20px}@media (min-width:768px){.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-25px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-25px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-25px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-30px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-30px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-30px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-30px}}</style><style type=\"text/css\">@charset \"UTF-8\";blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c{border-left:none;padding-left:0}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-28);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-40)}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c>p:first-of-type:before{content:\"\";margin-left:-.4em}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c>p:last-of-type:after{content:\"\"}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}@media (min-width:1180px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-44);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-52)}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite span{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite span{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}}blockquote.mdc-c-blockquote--is-align-center___l-q5n_990311c{text-align:center}blockquote.mdc-c-blockquote--is-align-right___yD7vc_990311c{text-align:right}@media (min-width:1180px){blockquote.mdc-c-blockquote--is-not-full-width___Dyvim_990311c{margin:0 auto;width:490px}}blockquote .mdc-c-blockquote__author-name___u4L7-_990311c{display:inline-block;text-decoration:inherit}</style><style type=\"text/css\">.mdc-c-progress-bar___PW5Xi_990311c{height:calc(var(--mdc-size-spacing-40)/2);overflow:hidden;position:relative}.mdc-c-progress-bar__progress___wQRDN_990311c{-webkit-appearance:none;appearance:none;height:inherit;overflow:hidden;position:absolute;width:100%}.mdc-c-progress-bar__progress___wQRDN_990311c::-webkit-progress-bar{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-progress-bar__progress___wQRDN_990311c::-moz-progress-bar{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-progress-bar__progress___wQRDN_990311c::-moz-progress-value{background-color:var(--mdc-color-neutral-gray-54);-moz-transition:width .6s ease-in-out;transition:width .6s ease-in-out}.mdc-c-progress-bar__progress___wQRDN_990311c::-webkit-progress-value{background-color:var(--mdc-color-neutral-gray-54);-webkit-transition:width .6s ease-in-out;transition:width .6s ease-in-out}.mdc-c-progress-bar__label___JDW5s_990311c{color:var(--mdc-color-neutral-white);font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);line-height:var(--mdc-size-line-height-20);position:absolute;top:0;transform:translate(calc(-100% - var(--mdc-size-spacing-8)));transition:left .6s ease-in-out}.mdc-c-progress-bar__label--align-outside___-YOop_990311c{color:var(--mdc-color-neutral-gray-54);padding-left:var(--mdc-size-spacing-8)}</style><style type=\"text/css\">.mdc-c-drop-down__rootmenu___yJzvz_990311c{color:var(--root-share-icon-color)!important;cursor:pointer;display:inline-grid!important;font-size:.75rem!important;font-weight:var(--mdc-font-weight-light)!important;gap:0!important;grid-auto-flow:row!important;line-height:1rem!important}.mdc-c-drop-down__rootmenu___yJzvz_990311c span:before{margin:auto}.mdc-c-drop-down__rootmenu--active___VHnk6_990311c,.mdc-c-drop-down__rootmenu___yJzvz_990311c:hover{color:var(--root-share-icon-color-hover)}.mdc-c-drop-down__menu___z9UVl_990311c{background:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-2);display:grid;gap:var(--mdc-size-spacing-16);padding:var(--mdc-size-spacing-24)}.mdc-c-drop-down__menu___z9UVl_990311c ul{margin:0;padding:0}.mdc-c-drop-down__menu___z9UVl_990311c ul li{list-style-type:none}.mdc-c-drop-down__menu___z9UVl_990311c ul li:not(:last-of-type){margin-bottom:var(--mdc-size-spacing-8)}.mdc-c-drop-down__menuitem___xIPFf_990311c{gap:var(--mdc-size-spacing-8)!important;line-height:1}.mdc-c-drop-down__arrow___O0eKP_990311c{position:absolute;transform:rotate(180deg)}.mdc-c-drop-down__arrow___O0eKP_990311c span{filter:drop-shadow(0 1px .5px rgba(5,28,44,.2));line-height:var(--mdc-size-line-height-24)}.mdc-c-drop-down__arrow___O0eKP_990311c span:before{color:var(--mdc-color-neutral-white)}</style><style type=\"text/css\">.mdc-c-bg-video___KqGb1_990311c{height:100%;object-fit:cover;width:100%}.mdc-c-play-pause-button___dscFo_990311c{bottom:var(--mdc-size-spacing-16);position:absolute;right:var(--mdc-size-spacing-24);z-index:var(--mdc-zindex-1)}.mdc-c-play-pause-button___dscFo_990311c span:before{background-color:var(--mdc-color-neutral-black)!important;color:var(--mdc-color-neutral-white)!important}.mdc-c-play-pause-button___dscFo_990311c span:hover:before{background-color:var(--mdc-color-palette-electric-blue)!important;box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}</style><style type=\"text/css\">.mdc-c-alert___HJ1s1_990311c{align-items:center;display:flex;gap:var(--mdc-size-spacing-8);justify-content:space-between;opacity:var(--mdc-opacity-100);padding:var(--mdc-size-spacing-16);transition-timing-function:ease-out}.mdc-c-alert--close-alert___BZpm3_990311c{opacity:0;transition:.2s}.mdc-c-alert--success___moj-j_990311c{background-color:var(--mdc-color-status-light-green);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-green)}.mdc-c-alert--error___iR23S_990311c{background-color:var(--mdc-color-status-light-red);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-red)}.mdc-c-alert--info___2ifXt_990311c{background-color:var(--mdc-color-status-light-blue);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-blue)}.mdc-c-alert--warning___2vdhU_990311c{background-color:var(--mdc-color-status-light-yellow);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-yellow)}.mdc-c-alert__message___CA3pW_990311c{display:flex;flex:1 1 0%;flex-wrap:wrap;justify-content:space-between}.mdc-c-alert__container___OY1LN_990311c{display:flex;gap:var(--mdc-size-spacing-16)}.mdc-c-alert__alert-icon___UDJog_990311c{flex:1 0 var(--mdc-size-spacing-24)}.mdc-c-alert__close-alert___UNT03_990311c{align-self:baseline;cursor:pointer;flex:0 0 var(--mdc-size-spacing-24)}.mdc-c-alert__close-alert___UNT03_990311c span:before{background-color:initial;color:var(--mdc-color-neutral-black)}.mdc-c-alert__close-alert___UNT03_990311c:focus span:before,.mdc-c-alert__close-alert___UNT03_990311c:hover span:before{background-color:#ffffff4d}</style><style type=\"text/css\">.mdc-c-loader___W8w3-_990311c{animation:spin___HfHqf_990311c 1.4s linear infinite;border:var(--mdc-size-spacing-4) solid var(--loader-border);border-radius:50%;border-top:var(--mdc-size-spacing-4) solid var(--loader-border-top);margin:0 auto}.mdc-c-loader--size-sm___K1ZMm_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-loader--size-md___EAQRY_990311c{height:var(--mdc-size-spacing-48);width:var(--mdc-size-spacing-48)}.mdc-c-loader--size-lg___0hH02_990311c{height:var(--mdc-size-spacing-72);width:var(--mdc-size-spacing-72)}.mdc-c-loader--border-1___w1cAp_990311c{border-width:1px}.mdc-c-loader--border-2___b8kJb_990311c{border-width:2px}.mdc-c-loader--border-3___AeSHf_990311c{border-width:3px}.mdc-c-loader--border-4___AsS32_990311c{border-width:4px}.mdc-c-loader--border-5___JRHFb_990311c{border-width:5px}.mdc-c-loader--inline___laBg6_990311c{margin:0}@keyframes spin___HfHqf_990311c{0%{transform:rotate(0deg)}to{transform:rotate(1turn)}}</style><style type=\"text/css\">.mdc-c-char-counter___vIMEm_990311c{color:var(--mdc-color-neutral-gray-70);font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);margin-left:auto}.mdc-c-char-counter--error___09qgB_990311c{color:var(--mdc-color-status-red)}</style><style type=\"text/css\">.mdc-c-form-control___ib-Ut_990311c{display:flex;flex-direction:column;gap:var(--mdc-size-spacing-8)}.mdc-c-form-control__label___ICXbu_990311c{color:var(--mdc-color-neutral-black);font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-24);margin:0}.mdc-c-form-control--error___9sMf7_990311c{color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__field___PTF2Y_990311c,.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__textarea___3V76M_990311c{border-color:var(--mdc-color-status-red);color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c label{color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__editor___TSbUw_990311c{border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-red);color:var(--mdc-color-status-red)}.mdc-c-form-control--size-sm___OAC6g_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);min-height:var(--mdc-size-spacing-32)}.mdc-c-form-control--size-md___nT0HS_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-42)}.mdc-c-form-control--size-lg___UeotQ_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-48)}.mdc-c-form-control--size-xl___8xbCi_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36);min-height:var(--mdc-size-spacing-56);padding:var(--mdc-size-spacing-24)}.mdc-c-form-control--size-xxl___LoPhp_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36);min-height:var(--mdc-size-spacing-64);padding:var(--mdc-size-spacing-32) var(--mdc-size-spacing-24)}.mdc-c-form-control__text-helper___gGlvN_990311c,.mdc-c-form-control__text-hint___rHwCJ_990311c{color:var(--mdc-color-neutral-gray-54)}.mdc-c-form-control__text-hint___rHwCJ_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-form-control__text-icon___ZRGsL_990311c{line-height:var(--mdc-size-spacing-4);margin-right:var(--mdc-size-spacing-4)}.mdc-c-form-control__text-error___grncf_990311c{color:var(--mdc-color-status-red);font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-form-control__control___oPCjw_990311c{position:relative}.mdc-c-form-control__show-icon___DcQyC_990311c{display:inline-flex;position:absolute;right:var(--mdc-size-spacing-16);top:50%;transform:translateY(-50%)}.mdc-c-form-control__show-icon--icon-left___bTByt_990311c{left:var(--mdc-size-spacing-16);right:inherit}.mdc-c-form-control__info-tooltip-wrapper___WvQ1m_990311c{align-items:center;display:flex;gap:var(--mdc-size-spacing-8)}.mdc-c-form-control___ib-Ut_990311c [class^=mdc-c-tooltip]{color:var(--mdc-color-neutral-gray-54);z-index:var(--mdc-zindex-1)}.mdc-c-form-control__textarea___3V76M_990311c{font-weight:var(--mdc-font-weight-regular);height:96px;max-height:600px}.mdc-c-form-control__textarea___3V76M_990311c.error___gKx3A_990311c{border-color:var(--mdc-color-status-red)}.mdc-c-form-control___ib-Ut_990311c .mdc-c-form-control__field--icon-right___W4s-t_990311c{padding-right:var(--mdc-size-spacing-56)}.mdc-c-form-control___ib-Ut_990311c .mdc-c-form-control__field--icon-left___YoJju_990311c{padding-left:var(--mdc-size-spacing-56)}.mdc-c-form-control__input-bottom___q3J5i_990311c{display:flex;gap:var(--mdc-size-spacing-32);justify-content:space-between}.mdc-c-form-control__input-bottom___q3J5i_990311c .mdc-c-form-control__container___1bzSs_990311c{display:flex;flex-direction:column}</style><style type=\"text/css\">.mdc-c-checkbox-control___UWECp_990311c{align-self:flex-start;cursor:pointer;display:flex;flex-direction:row;padding:var(--mdc-size-spacing-4) 0}.mdc-c-checkbox-control__wrapper___QhZEn_990311c{display:flex;flex-direction:row}.mdc-c-checkbox-control__label-container___xQnnT_990311c{display:flex;flex-direction:column;flex-grow:1;margin-left:var(--mdc-size-spacing-8)}.mdc-c-checkbox-control__hint___A79E-_990311c{overflow:hidden}.mdc-c-checkbox-control__display-name___DpsHy_990311c{font-weight:var(--mdc-font-weight-light);overflow:hidden}.mdc-c-checkbox-control__display-name___DpsHy_990311c span{border-bottom:var(--mdc-size-border-width-2) solid #0000;color:var(--mdc-color-neutral-black);font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24)}.mdc-c-checkbox-control__tooltip-content___a0MS3_990311c{margin-left:var(--mdc-size-spacing-8)}.mdc-c-checkbox-control___UWECp_990311c label.mdc-c-checkbox-control__display-name___DpsHy_990311c{text-transform:none}.mdc-c-checkbox-control___UWECp_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control___UWECp_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c{border-color:var(--mdc-color-palette-electric-blue)}.mdc-c-checkbox-control___UWECp_990311c:focus-within .mdc-c-checkbox-control__display-name___DpsHy_990311c span,.mdc-c-checkbox-control___UWECp_990311c:hover .mdc-c-checkbox-control__display-name___DpsHy_990311c span{border-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-palette-electric-blue);cursor:pointer}.mdc-c-checkbox-control__checkbox___pjkv3_990311c{align-items:center;-webkit-appearance:none;appearance:none;background:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);cursor:pointer;display:flex;flex:0 0 auto;flex-shrink:0;font-family:mck-icons;justify-content:center}.mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{background:var(--mdc-color-palette-electric-blue);border-color:var(--mdc-color-palette-electric-blue)}.mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked:after{color:var(--mdc-color-neutral-white);content:\"\\e612\"}.mdc-c-checkbox-control--size-md___-06Hq_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control--size-sm___z-REr_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-16);width:var(--mdc-size-spacing-16)}.mdc-c-checkbox-control--size-md___-06Hq_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c,.mdc-c-checkbox-control--size-sm___z-REr_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-checkbox-control--size-lg___1E9cE_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-24);width:var(--mdc-size-spacing-24)}.mdc-c-checkbox-control--size-xl___FfdJO_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-checkbox-control--size-xl___FfdJO_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-checkbox-control--size-xxl___YZHt-_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{font-size:var(--mdc-size-font-24);font-weight:bolder;height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-line-height-36);width:var(--mdc-size-spacing-40)}.mdc-c-checkbox-control--size-xxl___YZHt-_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c{border-color:var(--mdc-color-neutral-gray-30)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{border-color:var(--mdc-color-status-light-blue)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__display-name___DpsHy_990311c span,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__display-name___DpsHy_990311c span{border:none;color:var(--mdc-color-neutral-gray-30);cursor:not-allowed}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{background:var(--mdc-color-neutral-gray-18);border-color:var(--mdc-color-neutral-gray-30);cursor:not-allowed}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c span{color:var(--mdc-color-neutral-gray-30)}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{background:var(--mdc-color-status-light-blue);border-color:var(--mdc-color-status-light-blue)}.mdc-c-checkbox-group___K-viM_990311c{display:flex}.mdc-c-checkbox-group--direction-row___vFCK9_990311c{flex-direction:row;gap:var(--mdc-size-spacing-8);justify-content:flex-start}.mdc-c-checkbox-group--direction-column___VeWCA_990311c{align-items:flex-start;flex-direction:column;gap:var(--mdc-size-spacing-4)}</style><style type=\"text/css\">.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);cursor:pointer;font-family:mck-icons;opacity:0;position:absolute}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:not(:checked)+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c{display:none}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c{display:block}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c:before{background-color:var(--mdc-color-palette-electric-blue)}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label{cursor:pointer}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label span:before,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label span:before{box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c{border-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-palette-electric-blue)}.mdc-c-radial-checkbox-control--size-md___sYwDS_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c,.mdc-c-radial-checkbox-control--size-sm___FGVel_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-16);width:var(--mdc-size-spacing-16)}.mdc-c-radial-checkbox-control--size-lg___o6P1-_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-24);width:var(--mdc-size-spacing-24)}.mdc-c-radial-checkbox-control--size-xl___xTUNR_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-radial-checkbox-control--size-xxl___uDI7N_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{font-size:var(--mdc-size-font-24);font-weight:bolder;height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-line-height-36);width:var(--mdc-size-spacing-40)}</style><style type=\"text/css\">.mdc-c-tag___bvVWv_990311c{align-items:center;background-color:var(--mdc-color-neutral-gray-18);border-radius:var(--mdc-size-border-radius-4);color:var(--mdc-color-neutral-black);display:flex;font-family:var(--mdc-font-family-default-primary);font-size:var(--mdc-size-font-12);font-weight:var(--mdc-font-weight-light);gap:var(--mdc-size-spacing-8);line-height:var(--mdc-size-line-height-16);padding:var(--mdc-size-spacing-8);width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-tag___bvVWv_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag--with-hover___OE7lc_990311c:hover{background-color:var(--mdc-color-palette-electric-blue);box-shadow:var(--mdc-elevation-8);color:var(--mdc-color-neutral-white);cursor:pointer}.mdc-c-tag--with-hover___OE7lc_990311c:focus-visible{border:var(--mdc-size-border-width-1) solid var(--mdc-color-palette-electric-blue);outline:var(--mdc-size-border-width-4) solid #2155ff66}.mdc-c-tag--checked___BnJWp_990311c{background-color:var(--mdc-color-neutral-gray-70);color:var(--mdc-color-neutral-white)}</style><style type=\"text/css\">.mdc-c-select-custom___TOhaq_990311c{max-width:100%;position:relative}.mdc-c-select-custom--fit-content-width___epwhR_990311c{width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-select-custom__select-button___5fnAN_990311c{background-color:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);color:var(--mdc-color-neutral-black);cursor:pointer;grid-auto-flow:column;justify-content:space-between;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-8) var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);transition:all .12s linear}.mdc-c-select-custom__select-button--expanded___eNvKm_990311c{background-color:var(--mdc-color-palette-electric-blue);border:0;color:var(--mdc-color-neutral-white)}.mdc-c-select-custom__label___8vCRC_990311c{text-wrap:nowrap;overflow:hidden;text-overflow:ellipsis}.mdc-c-select-custom__list___xXyVs_990311c{background-color:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-8);margin:0;max-width:90vw;min-width:100%;padding:0;position:absolute;width:-webkit-max-content;width:max-content;z-index:1}.mdc-c-select-custom__list--collapsed___jyYdT_990311c{display:none}.mdc-c-select-custom__list--right___SwAN0_990311c{right:0}@media (min-width:768px){.mdc-c-select-custom__list___xXyVs_990311c{max-width:max(50vw,100%)}}.mdc-c-select-custom__list-item___7DeLO_990311c{cursor:pointer;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16)}.mdc-c-select-custom__list-item___7DeLO_990311c:focus,.mdc-c-select-custom__list-item___7DeLO_990311c:hover{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-select-custom__list-item--select-all___7U9Az_990311c{border-bottom:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-10)}.mdc-c-select-custom__footer___dMcSY_990311c{box-shadow:var(--mdc-elevation-8);padding:var(--mdc-size-spacing-16)}.mdc-c-select-custom___TOhaq_990311c [class^=mdc-c-button]{min-width:-webkit-fit-content;min-width:-moz-fit-content;min-width:fit-content}</style><style type=\"text/css\">.mdc-c-datepicker___706mw_990311c{color:var(--mdc-color-neutral-gray-80);position:relative}.mdc-c-datepicker__input___-ZW4z_990311c{padding-right:var(--mdc-size-spacing-32)!important}.mdc-c-datepicker__popper___AOPhF_990311c{background-color:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-4);font-family:var(--mdc-font-family-default-primary);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-24);z-index:var(--mdc-zindex-10)}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper-header___9HTov_990311c{align-items:center;display:flex;justify-content:space-between}.mdc-c-datepicker__popper-header___9HTov_990311c button{background:none;border:0;cursor:pointer;height:var(--mdc-size-spacing-40);outline:none;width:var(--mdc-size-spacing-40)}.mdc-c-datepicker__popper-header___9HTov_990311c button:hover{background-color:var(--mdc-color-neutral-gray-06);border-radius:50%}.mdc-c-datepicker__popper-year-nav___sRMUD_990311c{align-items:center;display:flex;flex:1;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-medium);gap:var(--mdc-size-spacing-8);justify-content:center;line-height:var(--mdc-size-line-height-24)}.mdc-c-datepicker__popper-year-nav___sRMUD_990311c select{border:none;cursor:pointer;outline:none;padding:0 var(--mdc-size-spacing-32) 0 0;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-datepicker__year-select___YPSz2_990311c{align-self:normal}.mdc-c-datepicker__reset-btn___tdJ-r_990311c{margin-right:var(--mdc-size-spacing-32)}.mdc-c-datepicker___706mw_990311c .react-datepicker__calendar-icon{color:var(--mdc-color-neutral-gray-80);cursor:pointer;position:absolute;right:var(--mdc-size-spacing-16);top:var(--mdc-size-spacing-8)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day-names{display:flex;font-size:var(--mdc-size-font-14);font-weight:var(--mdc-font-weight-medium);line-height:var(--mdc-size-line-height-20)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day,.mdc-c-datepicker___706mw_990311c .react-datepicker__day-name{height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-spacing-40);outline:none;text-align:center;width:var(--mdc-size-spacing-40)}.mdc-c-datepicker___706mw_990311c .react-datepicker__month{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-datepicker___706mw_990311c .react-datepicker__week{display:flex}.mdc-c-datepicker___706mw_990311c .react-datepicker__day{cursor:pointer}.mdc-c-datepicker___706mw_990311c .react-datepicker__day:hover{background-color:var(--mdc-color-neutral-gray-10)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--outside-month{color:var(--mdc-color-neutral-gray-30)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--today{border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-80);font-weight:var(--mdc-font-weight-bold)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--in-range,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--in-selecting-range{background-color:var(--mdc-color-status-light-blue)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--range-end,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--selected{background-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-neutral-white);font-weight:var(--mdc-font-weight-bold)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--range-end:hover,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--selected:hover{background-color:var(--mdc-color-status-dark-blue)}.mdc-c-datepicker___706mw_990311c .react-datepicker__today-button{display:flex;justify-content:space-between;padding-top:var(--mdc-size-spacing-8);width:100%}.mdc-c-datepicker___706mw_990311c .react-datepicker__aria-live{border:0;-webkit-clip-path:circle(0);clip-path:circle(0);height:0;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:0}</style><style type=\"text/css\">.mdc-c-modal__backdrop___-KX-s_990311c{align-items:center;animation-duration:.4s;animation-name:animatetop___aWqMX_990311c;background-color:#000c;inset:0;justify-content:center;overflow:auto;position:fixed;z-index:var(--mdc-zindex-20)}.mdc-c-modal__backdrop--bottom___le1-H_990311c{animation-name:animatebottom___4ILUZ_990311c}.mdc-c-modal__backdrop--hide___LW7W8_990311c{opacity:0}@keyframes animatetop___aWqMX_990311c{0%{opacity:0;top:-300px}to{opacity:1;top:0}}@keyframes animatebottom___4ILUZ_990311c{0%{bottom:-300px;opacity:0}to{bottom:0;opacity:1}}.mdc-c-modal__content___os-1D_990311c{box-sizing:border-box;margin:96px auto auto;max-width:624px;padding:var(--mdc-size-spacing-64);position:relative;width:100%}@media (max-width:1179px){.mdc-c-modal__content___os-1D_990311c{margin-top:var(--mdc-size-spacing-80)}}@media (max-width:767px){.mdc-c-modal__content___os-1D_990311c{margin:0;max-width:100%;min-height:100%;padding:var(--mdc-size-spacing-40)}}.mdc-c-modal__content--align-top___BfmM5_990311c{margin-top:0}.mdc-c-modal__content--align-bottom___-T7nI_990311c{animation-name:animatebottom___4ILUZ_990311c;bottom:0;position:absolute}.mdc-c-modal__content--full-width___hDjtB_990311c{max-width:100%}.mdc-c-modal__content--spacing-compact___5fP7H_990311c{padding:var(--mdc-size-spacing-40)}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__close-button___ZYOFu_990311c{position:absolute;right:var(--mdc-size-spacing-8);top:var(--mdc-size-spacing-8)}@media (min-width:768px){.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__close-button___ZYOFu_990311c{right:var(--mdc-size-spacing-16);top:var(--mdc-size-spacing-16)}}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__header___Fts7-_990311c{margin-bottom:var(--mdc-size-spacing-32)}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__header___Fts7-_990311c p{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28)}</style><style type=\"text/css\">:root .mdc-c-tabs___7eVdv_990311c,[data-module-theme=light] .mdc-c-tabs___7eVdv_990311c{--paddle-bg-right:linear-gradient(to right,#0000,var(--mdc-color-neutral-white) 50%);--paddle-bg-left:linear-gradient(to left,#0000,var(--mdc-color-neutral-white) 50%)}[data-module-theme=dark] .mdc-c-tabs___7eVdv_990311c{--paddle-bg-right:linear-gradient(to right,#0000,var(--mdc-color-palette-deep-blue) 50%);--paddle-bg-left:linear-gradient(to left,#0000,var(--mdc-color-palette-deep-blue) 50%)}.mdc-c-tabs___7eVdv_990311c{position:relative}.mdc-c-tabs__tablist-wrapper___dBa0k_990311c{overflow-x:scroll}.mdc-c-tabs__tablist-wrapper___dBa0k_990311c::-webkit-scrollbar{height:0;width:0}.mdc-c-tabs__tablist___I130n_990311c{grid-gap:var(--mdc-size-spacing-24);display:grid;grid-auto-flow:column;justify-content:start;margin:0;margin-bottom:calc(var(--mdc-size-border-width-1)*-1);padding:0;width:-webkit-max-content;width:max-content}.mdc-c-tabs__tablist--centered___UQ0o8_990311c{justify-content:center}.mdc-c-tabs__tab___IXSdl_990311c{border:0;border-bottom:var(--mdc-size-border-width-4) solid #0000;display:block;font-family:var(--mdc-font-family-default-primary);font-weight:var(--mdc-font-weight-light);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-4);width:-webkit-max-content;width:max-content}.mdc-c-tabs__tab___IXSdl_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab--is-active___G72D-_990311c{border-bottom-color:var(--button-minimal-tertiary-hover)}.mdc-c-tabs__tabpanel___chsU7_990311c{border-top:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-18);padding:var(--mdc-size-spacing-16) 0}.mdc-c-tabs__paddles___msvdU_990311c .mdc-c-tabs__paddle___Y09Ta_990311c{background-image:var(--paddle-bg-left);border:0;min-width:var(--mdc-size-spacing-16);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-24) var(--mdc-size-spacing-16) var(--mdc-size-spacing-8);position:absolute;top:0}.mdc-c-tabs__paddles___msvdU_990311c .mdc-c-tabs__paddle--right___KtnNh_990311c{background-image:var(--paddle-bg-right);padding-left:var(--mdc-size-spacing-24);padding-right:var(--mdc-size-spacing-8);right:0}.mdc-c-tabs__paddle___Y09Ta_990311c:focus,.mdc-c-tabs__tab___IXSdl_990311c:focus{outline:none}.mdc-c-tabs__paddle___Y09Ta_990311c:focus-visible,.mdc-c-tabs__tab___IXSdl_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default);outline-offset:calc(var(--mdc-size-border-width-4)*-1)}</style><style type=\"text/css\">.mdc-c-typeahead___31M3S_990311c{position:relative}.mdc-c-typeahead__menu___kINRW_990311c{background-color:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-30);box-shadow:var(--mdc-elevation-2);margin-top:var(--mdc-size-spacing-4);padding:0;width:100%;z-index:1}.mdc-c-typeahead__menu___kINRW_990311c ul{list-style:none;margin:0;padding:0}.mdc-c-typeahead__menu___kINRW_990311c ul li{cursor:pointer;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16)}.mdc-c-typeahead__menu-item--active___q5GP9_990311c{background-color:var(--mdc-color-neutral-gray-03);outline:none}</style><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/08dfc05290ce60e1.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-3464\" src=\"/_next/static/chunks/3464.caabbe0cce2df796.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-2453\" src=\"/_next/static/chunks/2453.5bbec710ffd42462.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/7f0894b6dca7827f.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-2169\" src=\"/_next/static/chunks/2169.db1ed0d7c6e757b7.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/46b1c7e4e497c465.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-5317\" src=\"/_next/static/chunks/5317.7ad5e77119c7b9d7.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-895\" src=\"/_next/static/chunks/895.63b261a2b180ec79.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-7044\" src=\"/_next/static/chunks/7044.d5c57fbc84841f29.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-906\" src=\"/_next/static/chunks/906.033c0adf90096a05.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-9829\" src=\"/_next/static/chunks/9829.1c1a2c713fe60a17.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/d4aec97cc669860d.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-3305\" src=\"/_next/static/chunks/3305.922e1efcae077965.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/5c2a9bc874cbce83.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-1649\" src=\"/_next/static/chunks/1649.100f3837f09cbcf8.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-1230\" src=\"/_next/static/chunks/1230.de91f4807c3ee7d1.js\"></script></head><body style=\"\"><div id=\"__next\" data-reactroot=\"\"><div class=\"Layout_mck-c-skipbar__K684J\"><a data-component=\"mdc-c-link\" href=\"#skipToMain\" class=\"mdc-c-button___U4iY2_990311c mdc-c-button--primary___Ed-lT_990311c mdc-c-button--size-medium\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Skip to main content</span></a></div><main class=\"mck-o-container--outer\" data-layer-region=\"body\" role=\"main\" id=\"skipToMain\"><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"dark\" data-module-background=\"deep-blue\" data-module-category=\"AnchoredHero\" class=\"ArticleDefault_mck-c-article-default__SfYQE\"><style>\n    .background-image-article-default {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/mipe10_frth.jpg?cq=50&mw=767&car=4:3&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          @media screen and (min-width: 768px){\n            \n    .background-image-article-default {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/mipe10_frth.jpg?cq=50&mw=1536&car=42:25&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          }\n        \n          @media screen and (min-width: 1180px){\n            \n    .background-image-article-default {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/mipe10_frth.jpg?cq=50&mw=1536&car=2:1&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          }\n        </style><div data-component=\"mdc-c-background-image\" class=\"mdc-c-bg-image___GJdv1_990311c background-image-article-default ArticleDefault_mck-c-article-default__parallax-container__fZ7Iq\"></div><div class=\"ArticleDefault_mck-c-article-default__gradient__Uu21n\"></div><div class=\"ArticleDefault_mck-c-article-default__wrapper-content__XOe9C\"><div class=\"mck-o-container\"><div class=\"mck-o-container--wrapped mck-o-container--mobile-spacing mdc-u-grid mdc-u-grid-col-lg-12\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-col-lg-start-1 mdc-u-grid-col-lg-span-10\"><div><h1 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-2 mck-u-animation-slide-down ArticleDefault_mck-c-article-default__heading__bv6rL\"><div>The microeconomics of personalized medicine</div></h1></div><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-10 mck-u-animation-blur-in-800 ArticleDefault_mck-c-article-default__description__sjoe9\"><div><time datetime=\"2010-02-01T00:00:00Z\">February 1, 2010</time> | Article</div></div></div></div></div></div></div><div class=\"mck-o-container\"><div class=\"mck-o-container--wrapped mck-o-container--mobile-spacing mdc-u-grid mdc-u-grid-gutter-xxl\"><section data-layer-region=\"article-body-header\" class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-animation-blur-in-400 byline-share-container\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-8 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-8 mdc-u-ts-9\"><span>By </span><span>Jerel Davis</span>,  <span>Philip Ma</span><span>,  and </span><a data-component=\"mdc-c-link\" href=\"/our-people/sarun-charumilind\" class=\"mdc-c-link-inline___7DRrt_990311c mdc-c-link-inline--secondary___YKoOK_990311c\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Saumya Sutaria</span></a></div><div class=\"mdc-u-grid-col-md-start-8 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-8 mdc-u-grid-col-lg-end-11 ArticleContent_mck-c-article-content__share-tools__kWRRw\"></div></section><section class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-animation-blur-in-400\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-5\"><div class=\"mck-u-links-inline\">Personalized medicine promises to increase the quality of clinical care and, in some cases, to decrease health care costs. The biggest hurdles are economic, not scientific.</div></div></div></section><main data-layer-region=\"article-body\" class=\"mdc-u-grid mdc-u-grid-gutter-xxl\"><div class=\"mdc-u-grid mdc-u-grid-col-1 mdc-u-grid-col-md-12\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><div class=\"mdc-o-content-body mck-u-dropcap\"><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"DownloadsSidebar_mck-c-downloads-sidebar__iFmyt mck-o-xs-right-span\"><div data-layer-region=\"downloads-right-rail\"><h3 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c\">DOWNLOADS</h3><div><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c\"><a data-component=\"mdc-c-link\" href=\"#/download/%2F~%2Fmedia%2Fmckinsey%2Findustries%2Flife%20sciences%2Four%20insights%2Fthe%20microeconomics%20of%20personalized%20medicine%2Fthe%20microeconomics%20of%20personalized%20medicine.pdf%3FshouldIndex%3Dfalse\" class=\"DownloadsSidebar_mck-c-downloads-sidebar__download-link__fPqFQ mdc-c-link___lBbY1_990311c\" target=\"_self\" data-layer-event-prefix=\"Download Link\" data-layer-action=\"click\" data-layer-report-type=\"Article\" data-layer-file-name=\"the-microeconomics of personalized medicine\" data-layer-report-name=\"the-microeconomics of personalized medicine>Article\"><span data-component=\"mdc-c-icon\" class=\"mdc-c-icon___oi7ef_990311c mdc-c-icon--size-md___yi5fA_990311c mck-download-icon\"></span><span class=\"mdc-c-link__label___Pfqtd_990311c\">Article (PDF-498 KB)</span></a></div></div></div></div> <p><strong>Diagnostics is the key</strong> to personalized medicine, a tailored approach to treatment based on the molecular analysis of genes, proteins, and metabolites. Yet although this approach has generated much excitement, few personalized-medicine tests have achieved high levels of clinical adoption. To understand better the challenges to the development and acceptance of personalized medicineand how to overcome themwe interviewed more than 60 leading experts in this and related fields<a href=\"#\" rel=\"#footnote1\" class=\"link-footnote\"><sup>1</sup></a> <span style=\"display:none\" class=\"tooltip\" id=\"footnote1\"><span class=\"footnote-content\"><span class=\"footnote-number\">1.</span><span class=\"footnote-text\">\nOur interview subjects included payers, providers, regulatory experts, executives of pharmaceutical and biotechnology companies, academic opinion leaders, and executives of diagnostics and clinical-laboratory companies.\n</span><span class=\"clear\"></span> </span><span class=\"footnote-bottom\"></span></span> and conducted microeconomic analyses of various stakeholder issues.</p><p>\nWe focus here on the US market, but the challenges are also relevant elsewhere. Our proposals for overcoming them could significantly accelerate the adoption of personalized medicine.</p><h2>Stakeholder incentives and challenges</h2><p>\nOur investigation highlighted three main obstacles to the advancement of personalized medicine: scientific challenges (a poor understanding of molecular mechanisms or a lack of molecular markers associated with some diseases, for example), economic challenges (poorly aligned incentives), and operational issues. Although scientific difficulties remain, the economic challenges and operational questions now seem to be the biggest hurdle. Operational issues can often be largely resolved within a particular stakeholder group, but correcting the incentive structure and modifying the relationships between stakeholders could be more complex.</p><h3>Payers</h3><p>\nInvestors and analysts have suggested that personalized medicine can dramatically reduce health care costs and help payers market products to the most attractive customers. Yet most payers have been slow to invest in personalized medicine. Leaders in payer organizations say that several factors could explain this reluctance. First, it is hard to identify which tests truly save costs. Second, the belief that it is difficult to track much earlier-stage and experimental testing leads to fears that although individual tests may not be very expensive, the overall eventual costs could be unjustifiably high. A third concern is the difficulty of enforcing standard protocols to ensure that physicians follow through with appropriate patient care based on test results. Fourth, test information could be misusedparticularly in the early stages of investigation and developmentwhich could harm patients. Finally, there is no longitudinal accounting, which would enable payers to capture long-term cost savings from near-term testing. </p><p>\nTo understand which tests avert costs, we analyzed various types of tests. Two primary factors determine a tests cost effectiveness from a payers perspective: per patient savings (the difference between the cost of treating a disease and the cost of the intervention indicated by the test) and the likelihood that a test suggests an intervention for any particular patient (Exhibit 1). Tests that help avoid the use of expensive therapies (for example, cancer therapies such as trastuzumab or imatinib), minimize costly adverse events (such as the warfarin dosing test), or delay expensive procedures can be extremely cost effective for payers. Although such tests cost $100 to $3,000 each, they save $600 to $28,000 per patient. Tests that save a small amount per patient or have a low probability of identifying patients requiring intervention are not cost effective. BRCA1 testing to predict the risk of breast cancer can save around $25,000 per patient identified, for example. But mutations are so rare in the general population that this test, which costs up to $3,000 per patient, is cost effective only when performed on a patient with a family history of breast cancer.</p> <div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 1</span></div><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c\"><div>Not all diagnostic tests cut costs for payers.</div></h5></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex1.svgz?cq=50&amp;cpy=Center\"><img alt=\"Web_MicroeconMedicine_ex1\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex1.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div><p>\nThe payers adoption of personalized-medicine tests is further complicated by the high customer turnover of many commercial payers in the United States. This makes it less economically attractive for payers to reimburse prophylactic tests that minimize the likelihood of conditions occurring much later in life: the costs accrue to the payer that screens the patient and performs the intervention, the benefits to the payer covering the patient when the disease actually arises. The pharmacoeconomics for the BRCA1 test illustrate the point (Exhibit 2). This longitudinal-accounting issue is particularly acute for diseases with a late or delayed onset: insurers for the elderlyfor example, the US Centers for Medicare and Medicaid Services (CMS)get the benefit of interventions paid for years earlier by commercial payers. Notably, payer systems that have low patient turnover, such as integrated systems like Kaiser Permanente in the United States or single-payer systems in Europe, are less exposed to this incentive challenge.</p> <div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 2</span></div><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c\"><div>Markers for prevention are least cost effective for programs with high patient turnover.</div></h5></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex2.svgz?cq=50&amp;cpy=Center\"><img alt=\"Web_MicroeconMedicine_ex2\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex2.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div><p>\nBecause the actual cost savings of personalized-medicine tests may not be known until a test has been on the market for some time, it will remain in the interests of payers to delay adopting such diagnostics until they can differentiate between cost-saving and cost-creating ones. The winning strategy for diagnostics companies may therefore be to collaborate with stakeholders whose economics are more aligned with theirs (for example, Kaiser Permanente, large self-insured employers, and the US Veterans Affairs system, which have relatively low membership turnover). Generating high-quality health economic evidence will provide the confidence that enables payers more rapidly to adopt tests and will align physicians incentives with patient care and outcomes rather than procedures. Such developments could create a source of competitive advantage for payers that are better at identifying and implementing policies to promote cost-saving diagnostics.</p><h3>Providers</h3><p>\nTodays procedure-based reimbursement system for providers also presents a challenge: provider economics create incentives for some personalized-medicine tests but discourage others. Physicians could be more likely to embrace tests that increase the number of procedures performed than tests that diminish procedure volume. A test that identifies three times more patients at high risk of colon cancer than current approaches do would align well with the interests of gastroenterologists, for example, since a patients lifetime value related to such a molecular diagnostic is around $2,000. Other tests may be cost neutral or have microeconomic disincentives. Onco<i>type</i> DX, a gene-based breast cancer diagnostic test used to assess the likelihood of benefit from chemotherapy, for example, reduces the number of patients that physicians treat with it and thus the revenue those patients generate. Yet Onco<i>type</i> DX has been widely adopted because of its clinical merit.</p><h3>Pharmaceutical and biotechnology companies</h3><p>\nBiomarkers (an indicator of a biological state) are now helping pharmaceutical and biotechnology companies to aid R&amp;D. In some cases, companies will develop these markers as companion diagnosticstests to identify a patients likelihood of responding to a drug or experiencing side effects. R&amp;D executives at 16 of the top 20 biopharmaceutical companies interviewed in a 2007 McKinsey survey indicated that, on average, 30 to 50 percent of drugs in development have an associated biomarker program and suggested that this number would probably increase. By contrast, the same executives also suggested that less than 10 percent of drugs that now have biomarker programs would be launched with a companion diagnostic over the next five to ten years (this is highly dependent on the disease area). </p><p>\nIn theory, companion diagnostics can improve R&amp;D productivity by decreasing trial sizes, reducing attrition, or increasing speed to market, as well as enhance commercial performance by boosting market share or supporting higher drug prices. Many companies, however, are moving slowly to use biomarkers and companion diagnostics: while the most aggressive players have biomarker programs for 100 percent and companion diagnostics for 30 percent or more of their compounds, the average company has far fewer (30 to 50 percent and less than 10 percent, respectively). Moreover, many experts we interviewed said that their companies hadnt prioritized companion diagnostics and were taking a cautious approach to investments. Scientific and clinical factors place some limits on the pace of development. In certain disease areas, understanding of molecular mechanisms is insufficient to select biomarkers at early stages of development. In others, there is no big clinical need for companion diagnostics. In many disease areas, however, companies are moving slowly despite scientific advances. </p><p>\nOur research suggests that the potential to generate greater value after marketing, through increasing prices and market share, is vastly more important for the economics of pharmaceutical and biotechnology companies than making development more productive (Exhibit 3). Indeed, companion diagnostics may do little to improve development productivity. Often, they might actually increase overall costs and delay development. Experts suggested that Phase II clinical trials must frequently be larger when companion diagnostics are employed. Trials often need to be designed with several potential candidate biomarkers in Phase II (and sometimes Phase III), as it is unclear which markers will be predictive. In addition, the US Food and Drug Administration (FDA) is likely to require that marker-negative patients be included in Phase III trials, given concerns that drugs could be used off-label by these patients. This is likely to eliminate the widely cited upside from smaller trials. Other commonly cited applications of personalized medicine during drug development also seem unlikely to improve drug-development productivity much.</p> <div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 3</span></div><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c\"><div>The potential to generate greater value after marketing is vastly more important for the economics of pharmaceutical and biotechnology companies than making development more productive.</div></h5></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex3.svgz?cq=50&amp;cpy=Center\"><img alt=\"Web_MicroeconMedicine_ex3\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex3.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div><p>\nNonetheless, companion diagnostics could create significant potential commercial benefits from increased market share and pricing power. Yet there are also significant risks, as companion diagnostics divide the treatable patient population into subsegments and can reduce market share. They are therefore most likely to create value for later-to-market entrants in crowded markets characterized by significant pricing flexibility.</p><p>\nIf two drugs are already on the market and relatively undifferentiated, for example, the third drug on the market is likely to capture a relatively small sharesay, 5 to 20 percent. A companion diagnostic that identifies a segment of patients who will respond especially well to a drug or will find it less toxic, and thereby enables higher pricing, could generate value. A key determinant is the payers price scrutiny and sensitivity, which varies dramatically by disease area, particularly in the United States. For instance, BiDil, a fixed-dose combination of two generic cardiovascular drugs (hydralazine hydrochloride and isosorbide dinitrate), has been approved by the FDA specifically for African Americans with heart failure. Attempts to charge a price premium faced aggressive differential copay tiering by payers, which contributed to lower-than-expected sales. In therapeutic classes where payers scrutinize prices less intensely (oncology drugs, for example), companies would be more likely to charge a premium and maintain coverage.</p><p>\nThese companies are rightly considering investing in personalized medicine in certain disease areas. To highlight those where near-term investment in companion diagnostics is most likely to occur, we segmented drug classes according to their scientific and commercial potential (Exhibit 4). This segmentation reflects not only quantitative factors but also qualitative factors from interviews. Our analysis indicates that companies are most likely to invest in diagnostics in areas such as oncology, immunology, and infectious disease. The segmentation also reveals disease areas where incentives are not aligned to drive investment, despite technical feasibility and clinical need. These areas, such as anticoagulants, antipsychotics, and antidepressants, are ripe for development by other organizations, such as diagnostics companies.</p> <div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit 4</span></div><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c\"><div>Companies are likely to invest in areas with the highest potential rewards.</div></h5></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex4.svgz?cq=50&amp;cpy=Center\"><img alt=\"Web_MicroeconMedicine_ex4\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex4.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div><p>\nCompanies should also realize that the payer environment is evolving rapidly and that personalized-medicine tools will increasingly be required to preserve value. Although pharmaceutical and biotechnology companies must be aware of areas where diagnostics can destroy value by subsegmenting existing markets, it will be equally important to prepare for the day when regulatory bodies will demand greater proof of patient outcomes to justify approval, reimbursement, and prices. Companies should thus act quickly to build the required capabilities and experience. </p><h3>Diagnostics companies</h3><p>\nCompanies that develop diagnostics and life science tools enable a wide variety of test types, including companion diagnostics (often in collaboration with a biotechnology or pharmaceutical company), early-stage diagnostics, disease recurrence and monitoring tests, adverse-drug-events tests, and genotypic-risk-marker analyses. However, diagnostics developers have faced difficulty capturing the full value they generate. Diagnostic tests are estimated to influence 60 to 70 percent of all treatment decisions, for example, yet account for only 5 percent of hospital costs and 2 percent of Medicare expenditures. Molecular diagnostics are often cited as a more attractive market segment than typical diagnostics, given the potential for higher prices ($100 to $3,000 per test, compared with $20 to $50 for a typical diagnostic test) and higher gross margins (50 to 70 percent for a sample molecular diagnostic, compared with 30 to 50 percent for most diagnostics of typical large laboratory companies). Indeed, a number of emerging companies, including Celera, Genomic Health, Myriad, Monogram Biosciences, and XDx, have successfully raised funding and developed innovative molecular-diagnostic tests.</p><p>\nUnfortunately, the molecular-diagnostics business case still holds significant risk (Exhibit 5) as a result of factors such as development costs, the timing of development and approval, time-to-payer coverage, rates of provider adoption, and peak sales prices. To understand these factors relative importance, we modeled the economics of a hypothetical start-up and then performed a sensitivity analysis using upside and downside scenarios for each variable.</p> <div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-inline-module-container mck-o-md-center\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg mdc-u-grid-col-sm-1 mdc-u-grid--align-start mdc-u-mb-3 GenericItem_mck-c-generic-item__sGwKL\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-gutter-xs GenericItem_mck-c-generic-item__content__gq1m0\"><div class=\"mck-c-eyebrow mdc-u-ts-10\"><span>Exhibit  5</span></div><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c\"><div>The molecular-diagnostics business case still holds significant risk.</div></h5></div></div></div><div class=\"mck-u-inline-module-border-top mck-u-inline-module-border-bottom\"><picture data-component=\"mdc-c-picture\" class=\"Exhibit_mck-c-exhibit__image__pyIDm\"><source media=\"(min-width: 768px)\" srcset=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex5.svgz?cq=50&amp;cpy=Center\"><img alt=\"Web_MicroeconMedicine_ex5\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20microeconomics%20of%20personalized%20medicine/svgz_web_microeconmedicine_ex5.svgz?cq=50&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mck-u-sr-only\">We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: <a href=\"mailto:McKinsey_Website_Accessibility@mckinsey.com\">McKinsey_Website_Accessibility@mckinsey.com</a></div></div><p>\nOur model, intended to test the importance of risk factors, was based on benchmarks from a few molecular-diagnostics businesses. It doesnt represent a specific company, and the economics of companies with products now on the market vary significantly. This model suggests that the expected ten-year net present value (NPV) of an average diagnostic test is around $15 million. The most important factors influencing profitability are the time to approval and the rate of payer adoption. If the time to approval is delayed by a year, the ten-year NPV becomes negative, at around $10 million. This finding is relevant, since it remains unclear how the FDA will regulate in vitro diagnostic multivariate index assays (IVDMIAs)tests like Onco<i>type</i> DX for breast cancer recurrence, which is already on the market. </p><p>\nAt the time of writing, the FDA had suggested that a 510(k) approval process for diagnostics may be sufficient for tests that are prognostic indicators, but pre-market-approval from the FDA will probably be required if a test directly influences therapy decisions. A pre-market-approval review is likely to increase time to market by at least a year. Nonetheless, good communication between the Center for Drug Evaluation and Research and the Office of In Vitro Diagnostic Device Evaluation and Safety may partially mitigate this problem through priority reviews. Approval timelines for other systems remain unclear. The European Medicines Agency and Japans Pharmaceuticals and Medical Devices Agency also have yet to establish clear guidelines for approving personalized-medicine tests.</p><p>\nThe case of Onco<i>type</i> DX demonstrates the challenge of slow coverage by payers. Although the test was launched in 2004, analysts and company estimates suggest it will be 2010 before all payers routinely cover it. Coverage stands at about 85 percent, contrasting starkly with typical adoption rates for new drugs, which are generally reimbursed immediately at launch or within the year in the United States. In Europe, drug coverage may take slightly longer, depending on the extent of the review, but is unlikely to take more than four yearsthe adoption timeline of Onco<i>type</i> DX.</p><p>\nStart-up diagnostics companies therefore face challenging economics. However, as more tests become available and payers, regulators, and molecular-diagnostics companies gain experience, development and adoption times are likely to shorten. Likewise, as the regulatory process becomes clearerbut potentially longerthe adoption rates of payers may also increase. Given their unease with personalized-medicine testing, it will therefore be advantageous for leading diagnostics companies to help shape the development of rigorous but efficient regulatory and approval standards.</p><h2>Potential catalysts for personalized medicine</h2><p>\nConversations and analyses conducted during the course of our investigation revealed four main catalysts that could significantly affect the adoption of personalized medicine in the near term.</p><h3>Regulatory environment</h3><p>\nFirst, regulatory bodies such as the FDA must improve the clarity and efficiency of regulatory-approval processes, both for stand-alone and companion diagnostics. These clarifications are critical to help diagnostics companies plan ahead and design trials. Our conversations with more than 60 experts indicate that the key questions regulatory bodies ought to address include the following:</p><ul class=\"leftContentUL\"><li><p>Should marker-negative patients be required for Phase III trials?</p></li><li><p>Will the use of retrospective analyses on archived samples be permitted for approving companion diagnostics (and if so, under what circumstances)?</p></li><li><p>What regulatory standards and oversight should be required to let personalized-medicine tests, especially laboratory-developed ones, be used in therapy decisions?</p></li></ul><p>\nFor regulations under consideration, the authorities must weigh short-term costs against long-term benefits. Current plans include basing the classification of tests as Class I, II, or III on the level of risk of the intended use. As a result of higher approval standards, IVDMIA changes promoting more rigorous evaluation of safety and effectiveness may have long-term benefits, encouraging faster adoption by payers and physicians. However, the near-term consequences may harm short-term market investments. </p><p>\nFor diagnostics companies, the approval process can actually be an opportunity to justify higher pricing by showing a willingness to set appropriately stringent standards and by shaping regulatory guidelines to bolster the industry and protect patients. The FDA should work to minimize approval delays resulting from higher standards and help mitigate any negative impact on investment in development. Leading pharmaceutical, biotechnology, and diagnostics companies should seek opportunities to help shape the development of these guidelines and standards. </p><p>\nTo drive changes in market incentives, regulators could decide not to require the collection of clinical data on marker-negative patients, thus lowering development costs. Concerns about the use of therapeutics in this population could be reduced through parallel moves by payers and regulatory bodies to increase barriers to off-label use. Furthermore, regulators could increase the flexibility of trial designs and even allow the approval of companion diagnostics on the basis of retrospective tests of the DX marker (that is, performed on archived samples). Finally, governments and regulators could directly reward the development of companion diagnostics by increasing the patent life for drugs developed with them, providing tax-based incentives, and continuing to award grants for R&amp;D.</p><h3>Payer coverage</h3><p>\nIn the United States, approval and reimbursement-coverage decisions are discrete processes with minimal coordination between the FDA and CMS. Uncertainty remains about how this coordination will work elsewhere in the world. Processes have not been establishedfor example, at the time of writing, the United Kingdoms National Institute for Health and Clinical Excellence (NICE) does not have any guidance on reviewing molecular-diagnostics tests. State payers, private payers, and diagnostics companies can help fuel growth in the personalized-medicine market by making coordinated efforts to improve the pace and process of coverage decisions.</p><p>\nOne step could be for CMS to take a lead in aligning the reimbursement process with the regulatory-approval process. Presubmission meetings to delineate data requirements for regulatory and coverage approval and ongoing joint reviews can facilitate interagency collaboration. Optimal alignment across the two agencies implies that if suitably stringent guidelines were set, CMS would provide coverage and adequately reimburse companies that meet the hurdles. Additional health economic data or regulatory approval for clinical claims, for instance, may be reasonable prerequisites for coverage and could thus help ensure adequate reimbursement, pricing, and value for diagnostics players.</p><p>\nThe development of formal guidelines could make decisions on coverage more transparent and efficient. CMS now typically makes coverage decisions for molecular diagnostics at the regional rather than national level. Decisions are thus made many times, based on different guidelines and processes and often with different outcomes. Private payers also lack clear guidelines for these decisions. Both CMS and private payers have an important role to play in shaping coverage and payment decisions. Private payers we interviewed are waiting to understand (and potentially follow) CMS coverage policies, as often occurs with therapeutics. </p><p>\nOne way to improve coverage guidelines in both systems and processes would be to establish an agency to assess the clinical and cost effectiveness of tests. This agencywhich could take the form of a third-party nonprofit agency, a consortium, or a new government agencycould be a coordinated effort by payers, CMS, pharmaceutical and biotechnology companies, and diagnostics players. The formation of new oversight agencies (for example, an FDA center for diagnostics) could also help. Notably, single-payer systems, such as those that predominate in Europe, have two advantages in adopting personalized medicine: they are not as susceptible to longitudinal-accounting issues, and coverage decisions can be less complex and involve fewer decision makers.</p><h3>Physician incentives</h3><p>\nAligning physicians incentives could further hasten adoption. In many countries, physicians get disproportionately higher rates for procedure-oriented services than for evaluation and management. They therefore often have a real financial disincentive to perform tests that might make further treatment unnecessary.</p><p>\nEfforts are under way to shift toward a more outcome-based approach to reimbursement, so that physicians will have incentives to use and act on appropriate personalized-medicine diagnostics. Yet to encourage adoption, payers should also work to develop a system ensuring that physicians are reimbursed for the test itself. Moreover, in the United States, personalized-medicine tests are now billed by a nonscalable approach called CPT<a href=\"#\" rel=\"#footnote2\" class=\"link-footnote\"><sup>2</sup></a> <span style=\"display:none\" class=\"tooltip\" id=\"footnote2\"><span class=\"footnote-content\"><span class=\"footnote-number\">2.</span><span class=\"footnote-text\">\nCurrent procedural terminology.\n</span><span class=\"clear\"></span> </span><span class=\"footnote-bottom\"></span></span> code stacking, which can encourage laboratories to game the system. Eventually, individual codes that are commensurate with a tests cost and value and that provide appropriate reimbursement to physicians will have to be developed for each molecular diagnostic.</p><h3>Investment by pharmaceutical and biotechnology companies</h3><p>\nPharmaceutical and biotechnology companies should take a long terminvestment view. Some already do: of the leaders we interviewed, those who have invested most heavily in personalized medicine suggested that they are renewing the focus on outcomes and clinical value in the process of drug discovery. They realize that the drugs their companies develop today will be entering markets with more competitors, more pricing pressure, and a higher bar for differentiated clinical outcomes. </p><p>\nAn aggressive move toward value- or outcomes-based pricing by CMS or private payers could greatly increase the financial value of personalized medicine and so the incentive to invest in it. One possibility might be innovative risk-sharing models for drug and diagnostic coverage. Payers could, for instance, follow the examples in Europe of bortezomib (Velcade) for multiple myeloma and the interferon-beta drugs for multiple sclerosis: reimbursement is contingent upon patient outcomes. Payers could also create innovative risk-sharing agreements with diagnostics companies. A test could, say, receive conditional, partial reimbursement for a number of years until its clinical effectiveness was definitively demonstrated, when the diagnostics company would be paid in full. The payer would limit cost exposure by covering part of the costs for a limited time; diagnostics companies would benefit from early coverage decisions.</p><p>\nOver the next few decades, the development of omics sciences (such as genomics) and supporting technologies will enable the creation of more and more personalized-medicine tests. Yet poorly aligned incentives for stakeholders could hamper their use. All stakeholders should therefore work together to reshape these incentives and so reap the benefits of personalized medicine.<br></p></div><div class=\"container-placeholder\"></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-xl\"><section role=\"contentinfo\" data-layer-region=\"article-about-authors\" class=\"mdc-u-grid mdc-u-grid-col-md-12 AboutAuthor_mck-c-about-author__nRJzu\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c mdc-u-align-center\">About the author(s)</h5><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-8 mck-u-links-inline mck-u-links-inline--secondary mdc-u-mt-5\"><div><p><strong>Jerel Davis</strong> is a consultant in McKinseys Silicon Valley office, where <strong>Saumya Sutaria</strong> and <strong>Laura Furstenthal</strong> are principals, and <strong>Edd Fleming</strong> and <strong>Philip Ma</strong> directors; <strong>Amar Desai</strong> is a consultant in the Los Angeles office; <strong>Troy Norris</strong> is a consultant in the New York office. A version of this article, titled The microeconomics of personalized medicine: todays challenge and tomorrows promise, was first published in <i>Nature Reviews Drug Discovery</i>, April 2009, Volume 8, No 4, pp. 27986. This article also appeared in <i>Invention reinvented</i>, a compendium of articles setting out McKinseys perspectives on pharmaceutical R&amp;D. To read other articles from the collection, please visit the <a href=\"http://www.mckinsey.com/Client_Service/Pharmaceuticals_and_Medical_Products\">pharmaceutical and medical products</a> section of mckinsey.com. </p></div></div></div></section><section class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-screen-only\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-5 mdc-u-grid-col-lg-end-9\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c mdc-u-align-center\">Explore a career with us</h5><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c mdc-c-link-container--align-center___ar3mu_990311c\"><a data-component=\"mdc-c-link\" href=\"/careers/search-jobs\" class=\"mdc-c-button___U4iY2_990311c mdc-c-button--secondary___Boipq_990311c mdc-c-button--size-large___jwpUy_990311c\" aria-label=\"Search Openings\" data-layer-event-prefix=\"CTA Link\" data-layer-action=\"click\" data-layer-category=\"careers\" data-layer-subcategory=\"search\" data-layer-text=\"Search Openings\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Search Openings</span></a></div></div></section></div></main></div><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"light\" data-module-background=\"lightest-grey\" data-module-category=\"StandalonePromo\" class=\"RelatedArticle_mck-c-article-related__GGA76 mck-u-screen-only\" data-layer-region=\"related-articles\"><div class=\"mdc-o-container__wrapper is-wrapped mdc-u-spaced-mobile\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-u-align-center\">Related Articles</h5><div class=\"mdc-u-grid mdc-u-grid-col-md-3 RelatedArticle_items-container__s2uD0\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/new-frontiers-in-pharma-r-and-38d-investment\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-newf-0 { aspect-ratio: 16/9 }</style><img alt=\"\" class=\"picture-uniqueKey-newf-0\" src=\"/next-static/images/module_item_placeholder.png?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/new-frontiers-in-pharma-r-and-38d-investment\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>New frontiers in pharma R&amp;D investment</div></a></h6></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/r-and-38d-in-emerging-markets-a-new-approach-for-a-new-era\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-r&amp-0 { aspect-ratio: 16/9 }</style><img alt=\"rdem10_frth\" class=\"picture-uniqueKey-r&amp;amp-0\" src=\"/~/media/mckinsey/featured%20insights/emerging%20markets/r%20and%2038d%20in%20emerging%20markets%20a%20new%20approach%20for%20a%20new%20era/rdem10_frth.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/r-and-38d-in-emerging-markets-a-new-approach-for-a-new-era\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>R&amp;D in emerging markets: A new approach for a new era</div></a></h6></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/the-road-to-positive-r-and-38d-returns\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-ther-0 { aspect-ratio: 16/9 }</style><img alt=\"ropo10_frth\" class=\"picture-uniqueKey-ther-0\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/the%20road%20to%20positive%20r%20and%2038d%20returns/ropo10_frth.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/the-road-to-positive-r-and-38d-returns\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>The road to positive R&amp;D returns</div></a></h6></div></div></div></div></div></div></div></main><div class=\"mck-u-sr-only\" role=\"log\" aria-live=\"polite\" aria-relevant=\"additions\" aria-atomic=\"true\"></div></div><script id=\"__NEXT_DATA__\" type=\"application/json\">{\"props\":{\"pageProps\":{\"locale\":\"en\",\"dictionary\":{},\"sitecoreContext\":{\"route\":{\"name\":\"The microeconomics of personalized medicine\",\"displayName\":\"The microeconomics of personalized medicine\",\"fields\":null,\"databaseName\":\"web\",\"deviceId\":\"fe5d7fdf-89c0-4d99-9aa3-b5fbd009c9f3\",\"itemId\":\"1b13b0b4-89b5-4f5c-b948-ee5f5e9463cb\",\"itemLanguage\":\"en\",\"itemVersion\":1,\"layoutId\":\"ae753eb4-a035-40b4-83bf-4b4438df6742\",\"templateId\":\"683910db-02ba-40ba-92e7-726c880160a9\",\"templateName\":\"ArticleJSS\",\"placeholders\":{\"jss-main\":[{\"uid\":\"232bb7e9-289f-492d-a916-2b6185e44a84\",\"componentName\":\"ArticleTemplate\",\"dataSource\":\"\",\"fields\":{\"data\":{\"articleTemplate\":{\"title\":{\"jsonValue\":{\"value\":\"The microeconomics of personalized medicine\"}},\"sEOTitle\":{\"value\":\"\"},\"description\":{\"jsonValue\":{\"value\":\"Personalized medicine promises to increase the quality of clinical care and, in some cases, to decrease health care costs. The biggest hurdles are economic, not scientific.\"}},\"sEODescription\":{\"value\":\"\"},\"displayDate\":{\"jsonValue\":{\"value\":\"2010-02-01T00:00:00Z\"}},\"body\":{\"value\":\"[[DownloadsSidebar]] \\u003cp\\u003e\\u003cstrong\\u003eDiagnostics is the key\\u003c/strong\\u003e to personalized medicine, a tailored approach to treatment based on the molecular analysis of genes, proteins, and metabolites. Yet although this approach has generated much excitement, few personalized-medicine tests have achieved high levels of clinical adoption. To understand better the challenges to the development and acceptance of personalized medicineand how to overcome themwe interviewed more than 60 leading experts in this and related fields\\u003ca class='link-footnote' rel='#footnote1' href='#' onclick='return false;'\\u003e\\u003csup\\u003e1\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan id='footnote1' class='tooltip' style='display:none;'\\u003e\\u003cspan class='footnote-content'\\u003e\\u003cspan class='footnote-number'\\u003e1.\\u003c/span\\u003e\\u003cspan class='footnote-text'\\u003e\\r\\nOur interview subjects included payers, providers, regulatory experts, executives of pharmaceutical and biotechnology companies, academic opinion leaders, and executives of diagnostics and clinical-laboratory companies.\\r\\n\\u003c/span\\u003e\\u003cspan class='clear'\\u003e\\u003c/span\\u003e \\u003c/span\\u003e\\u003cspan class='footnote-bottom'\\u003e\\u003c/span\\u003e\\u003c/span\\u003e and conducted microeconomic analyses of various stakeholder issues.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nWe focus here on the US market, but the challenges are also relevant elsewhere. Our proposals for overcoming them could significantly accelerate the adoption of personalized medicine.\\u003c/p\\u003e\\u003ch2\\u003eStakeholder incentives and challenges\\u003c/h2\\u003e\\u003cp\\u003e\\r\\nOur investigation highlighted three main obstacles to the advancement of personalized medicine: scientific challenges (a poor understanding of molecular mechanisms or a lack of molecular markers associated with some diseases, for example), economic challenges (poorly aligned incentives), and operational issues. Although scientific difficulties remain, the economic challenges and operational questions now seem to be the biggest hurdle. Operational issues can often be largely resolved within a particular stakeholder group, but correcting the incentive structure and modifying the relationships between stakeholders could be more complex.\\u003c/p\\u003e\\u003ch3 \\u003ePayers\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nInvestors and analysts have suggested that personalized medicine can dramatically reduce health care costs and help payers market products to the most attractive customers. Yet most payers have been slow to invest in personalized medicine. Leaders in payer organizations say that several factors could explain this reluctance. First, it is hard to identify which tests truly save costs. Second, the belief that it is difficult to track much earlier-stage and experimental testing leads to fears that although individual tests may not be very expensive, the overall eventual costs could be unjustifiably high. A third concern is the difficulty of enforcing standard protocols to ensure that physicians follow through with appropriate patient care based on test results. Fourth, test information could be misusedparticularly in the early stages of investigation and developmentwhich could harm patients. Finally, there is no longitudinal accounting, which would enable payers to capture long-term cost savings from near-term testing. \\u003c/p\\u003e\\u003cp\\u003e\\r\\nTo understand which tests avert costs, we analyzed various types of tests. Two primary factors determine a tests cost effectiveness from a payers perspective: per patient savings (the difference between the cost of treating a disease and the cost of the intervention indicated by the test) and the likelihood that a test suggests an intervention for any particular patient (Exhibit 1). Tests that help avoid the use of expensive therapies (for example, cancer therapies such as trastuzumab or imatinib), minimize costly adverse events (such as the warfarin dosing test), or delay expensive procedures can be extremely cost effective for payers. Although such tests cost $100 to $3,000 each, they save $600 to $28,000 per patient. Tests that save a small amount per patient or have a low probability of identifying patients requiring intervention are not cost effective. BRCA1 testing to predict the risk of breast cancer can save around $25,000 per patient identified, for example. But mutations are so rare in the general population that this test, which costs up to $3,000 per patient, is cost effective only when performed on a patient with a family history of breast cancer.\\u003c/p\\u003e [[exhibit 1]]\\u003cp\\u003e\\r\\nThe payers adoption of personalized-medicine tests is further complicated by the high customer turnover of many commercial payers in the United States. This makes it less economically attractive for payers to reimburse prophylactic tests that minimize the likelihood of conditions occurring much later in life: the costs accrue to the payer that screens the patient and performs the intervention, the benefits to the payer covering the patient when the disease actually arises. The pharmacoeconomics for the BRCA1 test illustrate the point (Exhibit 2). This longitudinal-accounting issue is particularly acute for diseases with a late or delayed onset: insurers for the elderlyfor example, the US Centers for Medicare and Medicaid Services (CMS)get the benefit of interventions paid for years earlier by commercial payers. Notably, payer systems that have low patient turnover, such as integrated systems like Kaiser Permanente in the United States or single-payer systems in Europe, are less exposed to this incentive challenge.\\u003c/p\\u003e [[exhibit 2]]\\u003cp\\u003e\\r\\nBecause the actual cost savings of personalized-medicine tests may not be known until a test has been on the market for some time, it will remain in the interests of payers to delay adopting such diagnostics until they can differentiate between cost-saving and cost-creating ones. The winning strategy for diagnostics companies may therefore be to collaborate with stakeholders whose economics are more aligned with theirs (for example, Kaiser Permanente, large self-insured employers, and the US Veterans Affairs system, which have relatively low membership turnover). Generating high-quality health economic evidence will provide the confidence that enables payers more rapidly to adopt tests and will align physicians incentives with patient care and outcomes rather than procedures. Such developments could create a source of competitive advantage for payers that are better at identifying and implementing policies to promote cost-saving diagnostics.\\u003c/p\\u003e\\u003ch3 \\u003eProviders\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nTodays procedure-based reimbursement system for providers also presents a challenge: provider economics create incentives for some personalized-medicine tests but discourage others. Physicians could be more likely to embrace tests that increase the number of procedures performed than tests that diminish procedure volume. A test that identifies three times more patients at high risk of colon cancer than current approaches do would align well with the interests of gastroenterologists, for example, since a patients lifetime value related to such a molecular diagnostic is around $2,000. Other tests may be cost neutral or have microeconomic disincentives. Onco\\u003ci\\u003etype\\u003c/i\\u003e DX, a gene-based breast cancer diagnostic test used to assess the likelihood of benefit from chemotherapy, for example, reduces the number of patients that physicians treat with it and thus the revenue those patients generate. Yet Onco\\u003ci\\u003etype\\u003c/i\\u003e DX has been widely adopted because of its clinical merit.\\u003c/p\\u003e\\u003ch3 \\u003ePharmaceutical and biotechnology companies\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nBiomarkers (an indicator of a biological state) are now helping pharmaceutical and biotechnology companies to aid R\\u0026D. In some cases, companies will develop these markers as companion diagnosticstests to identify a patients likelihood of responding to a drug or experiencing side effects. R\\u0026D executives at 16 of the top 20 biopharmaceutical companies interviewed in a 2007 McKinsey survey indicated that, on average, 30 to 50 percent of drugs in development have an associated biomarker program and suggested that this number would probably increase. By contrast, the same executives also suggested that less than 10 percent of drugs that now have biomarker programs would be launched with a companion diagnostic over the next five to ten years (this is highly dependent on the disease area). \\u003c/p\\u003e\\u003cp\\u003e\\r\\nIn theory, companion diagnostics can improve R\\u0026D productivity by decreasing trial sizes, reducing attrition, or increasing speed to market, as well as enhance commercial performance by boosting market share or supporting higher drug prices. Many companies, however, are moving slowly to use biomarkers and companion diagnostics: while the most aggressive players have biomarker programs for 100 percent and companion diagnostics for 30 percent or more of their compounds, the average company has far fewer (30 to 50 percent and less than 10 percent, respectively). Moreover, many experts we interviewed said that their companies hadnt prioritized companion diagnostics and were taking a cautious approach to investments. Scientific and clinical factors place some limits on the pace of development. In certain disease areas, understanding of molecular mechanisms is insufficient to select biomarkers at early stages of development. In others, there is no big clinical need for companion diagnostics. In many disease areas, however, companies are moving slowly despite scientific advances. \\u003c/p\\u003e\\u003cp\\u003e\\r\\nOur research suggests that the potential to generate greater value after marketing, through increasing prices and market share, is vastly more important for the economics of pharmaceutical and biotechnology companies than making development more productive (Exhibit 3). Indeed, companion diagnostics may do little to improve development productivity. Often, they might actually increase overall costs and delay development. Experts suggested that Phase II clinical trials must frequently be larger when companion diagnostics are employed. Trials often need to be designed with several potential candidate biomarkers in Phase II (and sometimes Phase III), as it is unclear which markers will be predictive. In addition, the US Food and Drug Administration (FDA) is likely to require that marker-negative patients be included in Phase III trials, given concerns that drugs could be used off-label by these patients. This is likely to eliminate the widely cited upside from smaller trials. Other commonly cited applications of personalized medicine during drug development also seem unlikely to improve drug-development productivity much.\\u003c/p\\u003e [[exhibit 3]]\\u003cp\\u003e\\r\\nNonetheless, companion diagnostics could create significant potential commercial benefits from increased market share and pricing power. Yet there are also significant risks, as companion diagnostics divide the treatable patient population into subsegments and can reduce market share. They are therefore most likely to create value for later-to-market entrants in crowded markets characterized by significant pricing flexibility.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nIf two drugs are already on the market and relatively undifferentiated, for example, the third drug on the market is likely to capture a relatively small sharesay, 5 to 20 percent. A companion diagnostic that identifies a segment of patients who will respond especially well to a drug or will find it less toxic, and thereby enables higher pricing, could generate value. A key determinant is the payers price scrutiny and sensitivity, which varies dramatically by disease area, particularly in the United States. For instance, BiDil, a fixed-dose combination of two generic cardiovascular drugs (hydralazine hydrochloride and isosorbide dinitrate), has been approved by the FDA specifically for African Americans with heart failure. Attempts to charge a price premium faced aggressive differential copay tiering by payers, which contributed to lower-than-expected sales. In therapeutic classes where payers scrutinize prices less intensely (oncology drugs, for example), companies would be more likely to charge a premium and maintain coverage.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nThese companies are rightly considering investing in personalized medicine in certain disease areas. To highlight those where near-term investment in companion diagnostics is most likely to occur, we segmented drug classes according to their scientific and commercial potential (Exhibit 4). This segmentation reflects not only quantitative factors but also qualitative factors from interviews. Our analysis indicates that companies are most likely to invest in diagnostics in areas such as oncology, immunology, and infectious disease. The segmentation also reveals disease areas where incentives are not aligned to drive investment, despite technical feasibility and clinical need. These areas, such as anticoagulants, antipsychotics, and antidepressants, are ripe for development by other organizations, such as diagnostics companies.\\u003c/p\\u003e [[exhibit 4]]\\u003cp\\u003e\\r\\nCompanies should also realize that the payer environment is evolving rapidly and that personalized-medicine tools will increasingly be required to preserve value. Although pharmaceutical and biotechnology companies must be aware of areas where diagnostics can destroy value by subsegmenting existing markets, it will be equally important to prepare for the day when regulatory bodies will demand greater proof of patient outcomes to justify approval, reimbursement, and prices. Companies should thus act quickly to build the required capabilities and experience. \\u003c/p\\u003e\\u003ch3 \\u003eDiagnostics companies\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nCompanies that develop diagnostics and life science tools enable a wide variety of test types, including companion diagnostics (often in collaboration with a biotechnology or pharmaceutical company), early-stage diagnostics, disease recurrence and monitoring tests, adverse-drug-events tests, and genotypic-risk-marker analyses. However, diagnostics developers have faced difficulty capturing the full value they generate. Diagnostic tests are estimated to influence 60 to 70 percent of all treatment decisions, for example, yet account for only 5 percent of hospital costs and 2 percent of Medicare expenditures. Molecular diagnostics are often cited as a more attractive market segment than typical diagnostics, given the potential for higher prices ($100 to $3,000 per test, compared with $20 to $50 for a typical diagnostic test) and higher gross margins (50 to 70 percent for a sample molecular diagnostic, compared with 30 to 50 percent for most diagnostics of typical large laboratory companies). Indeed, a number of emerging companies, including Celera, Genomic Health, Myriad, Monogram Biosciences, and XDx, have successfully raised funding and developed innovative molecular-diagnostic tests.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nUnfortunately, the molecular-diagnostics business case still holds significant risk (Exhibit 5) as a result of factors such as development costs, the timing of development and approval, time-to-payer coverage, rates of provider adoption, and peak sales prices. To understand these factors relative importance, we modeled the economics of a hypothetical start-up and then performed a sensitivity analysis using upside and downside scenarios for each variable.\\u003c/p\\u003e [[exhibit 5]]\\u003cp\\u003e\\r\\nOur model, intended to test the importance of risk factors, was based on benchmarks from a few molecular-diagnostics businesses. It doesnt represent a specific company, and the economics of companies with products now on the market vary significantly. This model suggests that the expected ten-year net present value (NPV) of an average diagnostic test is around $15 million. The most important factors influencing profitability are the time to approval and the rate of payer adoption. If the time to approval is delayed by a year, the ten-year NPV becomes negative, at around $10 million. This finding is relevant, since it remains unclear how the FDA will regulate in vitro diagnostic multivariate index assays (IVDMIAs)tests like Onco\\u003ci\\u003etype\\u003c/i\\u003e DX for breast cancer recurrence, which is already on the market. \\u003c/p\\u003e\\u003cp\\u003e\\r\\nAt the time of writing, the FDA had suggested that a 510(k) approval process for diagnostics may be sufficient for tests that are prognostic indicators, but pre-market-approval from the FDA will probably be required if a test directly influences therapy decisions. A pre-market-approval review is likely to increase time to market by at least a year. Nonetheless, good communication between the Center for Drug Evaluation and Research and the Office of In Vitro Diagnostic Device Evaluation and Safety may partially mitigate this problem through priority reviews. Approval timelines for other systems remain unclear. The European Medicines Agency and Japans Pharmaceuticals and Medical Devices Agency also have yet to establish clear guidelines for approving personalized-medicine tests.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nThe case of Onco\\u003ci\\u003etype\\u003c/i\\u003e DX demonstrates the challenge of slow coverage by payers. Although the test was launched in 2004, analysts and company estimates suggest it will be 2010 before all payers routinely cover it. Coverage stands at about 85 percent, contrasting starkly with typical adoption rates for new drugs, which are generally reimbursed immediately at launch or within the year in the United States. In Europe, drug coverage may take slightly longer, depending on the extent of the review, but is unlikely to take more than four yearsthe adoption timeline of Onco\\u003ci\\u003etype\\u003c/i\\u003e DX.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nStart-up diagnostics companies therefore face challenging economics. However, as more tests become available and payers, regulators, and molecular-diagnostics companies gain experience, development and adoption times are likely to shorten. Likewise, as the regulatory process becomes clearerbut potentially longerthe adoption rates of payers may also increase. Given their unease with personalized-medicine testing, it will therefore be advantageous for leading diagnostics companies to help shape the development of rigorous but efficient regulatory and approval standards.\\u003c/p\\u003e\\u003ch2\\u003ePotential catalysts for personalized medicine\\u003c/h2\\u003e\\u003cp\\u003e\\r\\nConversations and analyses conducted during the course of our investigation revealed four main catalysts that could significantly affect the adoption of personalized medicine in the near term.\\u003c/p\\u003e\\u003ch3 \\u003eRegulatory environment\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nFirst, regulatory bodies such as the FDA must improve the clarity and efficiency of regulatory-approval processes, both for stand-alone and companion diagnostics. These clarifications are critical to help diagnostics companies plan ahead and design trials. Our conversations with more than 60 experts indicate that the key questions regulatory bodies ought to address include the following:\\u003c/p\\u003e\\u003cul class=\\\"leftContentUL\\\"\\u003e\\u003cli\\u003e\\u003cp\\u003eShould marker-negative patients be required for Phase III trials?\\u003c/p\\u003e\\u003c/li\\u003e\\u003cli\\u003e\\u003cp\\u003eWill the use of retrospective analyses on archived samples be permitted for approving companion diagnostics (and if so, under what circumstances)?\\u003c/p\\u003e\\u003c/li\\u003e\\u003cli\\u003e\\u003cp\\u003eWhat regulatory standards and oversight should be required to let personalized-medicine tests, especially laboratory-developed ones, be used in therapy decisions?\\u003c/p\\u003e\\u003c/li\\u003e\\u003c/ul\\u003e\\u003cp\\u003e\\r\\nFor regulations under consideration, the authorities must weigh short-term costs against long-term benefits. Current plans include basing the classification of tests as Class I, II, or III on the level of risk of the intended use. As a result of higher approval standards, IVDMIA changes promoting more rigorous evaluation of safety and effectiveness may have long-term benefits, encouraging faster adoption by payers and physicians. However, the near-term consequences may harm short-term market investments. \\u003c/p\\u003e\\u003cp\\u003e\\r\\nFor diagnostics companies, the approval process can actually be an opportunity to justify higher pricing by showing a willingness to set appropriately stringent standards and by shaping regulatory guidelines to bolster the industry and protect patients. The FDA should work to minimize approval delays resulting from higher standards and help mitigate any negative impact on investment in development. Leading pharmaceutical, biotechnology, and diagnostics companies should seek opportunities to help shape the development of these guidelines and standards. \\u003c/p\\u003e\\u003cp\\u003e\\r\\nTo drive changes in market incentives, regulators could decide not to require the collection of clinical data on marker-negative patients, thus lowering development costs. Concerns about the use of therapeutics in this population could be reduced through parallel moves by payers and regulatory bodies to increase barriers to off-label use. Furthermore, regulators could increase the flexibility of trial designs and even allow the approval of companion diagnostics on the basis of retrospective tests of the DX marker (that is, performed on archived samples). Finally, governments and regulators could directly reward the development of companion diagnostics by increasing the patent life for drugs developed with them, providing tax-based incentives, and continuing to award grants for R\\u0026D.\\u003c/p\\u003e\\u003ch3 \\u003ePayer coverage\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nIn the United States, approval and reimbursement-coverage decisions are discrete processes with minimal coordination between the FDA and CMS. Uncertainty remains about how this coordination will work elsewhere in the world. Processes have not been establishedfor example, at the time of writing, the United Kingdoms National Institute for Health and Clinical Excellence (NICE) does not have any guidance on reviewing molecular-diagnostics tests. State payers, private payers, and diagnostics companies can help fuel growth in the personalized-medicine market by making coordinated efforts to improve the pace and process of coverage decisions.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nOne step could be for CMS to take a lead in aligning the reimbursement process with the regulatory-approval process. Presubmission meetings to delineate data requirements for regulatory and coverage approval and ongoing joint reviews can facilitate interagency collaboration. Optimal alignment across the two agencies implies that if suitably stringent guidelines were set, CMS would provide coverage and adequately reimburse companies that meet the hurdles. Additional health economic data or regulatory approval for clinical claims, for instance, may be reasonable prerequisites for coverage and could thus help ensure adequate reimbursement, pricing, and value for diagnostics players.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nThe development of formal guidelines could make decisions on coverage more transparent and efficient. CMS now typically makes coverage decisions for molecular diagnostics at the regional rather than national level. Decisions are thus made many times, based on different guidelines and processes and often with different outcomes. Private payers also lack clear guidelines for these decisions. Both CMS and private payers have an important role to play in shaping coverage and payment decisions. Private payers we interviewed are waiting to understand (and potentially follow) CMS coverage policies, as often occurs with therapeutics. \\u003c/p\\u003e\\u003cp\\u003e\\r\\nOne way to improve coverage guidelines in both systems and processes would be to establish an agency to assess the clinical and cost effectiveness of tests. This agencywhich could take the form of a third-party nonprofit agency, a consortium, or a new government agencycould be a coordinated effort by payers, CMS, pharmaceutical and biotechnology companies, and diagnostics players. The formation of new oversight agencies (for example, an FDA center for diagnostics) could also help. Notably, single-payer systems, such as those that predominate in Europe, have two advantages in adopting personalized medicine: they are not as susceptible to longitudinal-accounting issues, and coverage decisions can be less complex and involve fewer decision makers.\\u003c/p\\u003e\\u003ch3 \\u003ePhysician incentives\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nAligning physicians incentives could further hasten adoption. In many countries, physicians get disproportionately higher rates for procedure-oriented services than for evaluation and management. They therefore often have a real financial disincentive to perform tests that might make further treatment unnecessary.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nEfforts are under way to shift toward a more outcome-based approach to reimbursement, so that physicians will have incentives to use and act on appropriate personalized-medicine diagnostics. Yet to encourage adoption, payers should also work to develop a system ensuring that physicians are reimbursed for the test itself. Moreover, in the United States, personalized-medicine tests are now billed by a nonscalable approach called CPT\\u003ca class='link-footnote' rel='#footnote2' href='#' onclick='return false;'\\u003e\\u003csup\\u003e2\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan id='footnote2' class='tooltip' style='display:none;'\\u003e\\u003cspan class='footnote-content'\\u003e\\u003cspan class='footnote-number'\\u003e2.\\u003c/span\\u003e\\u003cspan class='footnote-text'\\u003e\\r\\nCurrent procedural terminology.\\r\\n\\u003c/span\\u003e\\u003cspan class='clear'\\u003e\\u003c/span\\u003e \\u003c/span\\u003e\\u003cspan class='footnote-bottom'\\u003e\\u003c/span\\u003e\\u003c/span\\u003e code stacking, which can encourage laboratories to game the system. Eventually, individual codes that are commensurate with a tests cost and value and that provide appropriate reimbursement to physicians will have to be developed for each molecular diagnostic.\\u003c/p\\u003e\\u003ch3 \\u003eInvestment by pharmaceutical and biotechnology companies\\u003c/h3\\u003e\\u003cp\\u003e\\r\\nPharmaceutical and biotechnology companies should take a long terminvestment view. Some already do: of the leaders we interviewed, those who have invested most heavily in personalized medicine suggested that they are renewing the focus on outcomes and clinical value in the process of drug discovery. They realize that the drugs their companies develop today will be entering markets with more competitors, more pricing pressure, and a higher bar for differentiated clinical outcomes. \\u003c/p\\u003e\\u003cp\\u003e\\r\\nAn aggressive move toward value- or outcomes-based pricing by CMS or private payers could greatly increase the financial value of personalized medicine and so the incentive to invest in it. One possibility might be innovative risk-sharing models for drug and diagnostic coverage. Payers could, for instance, follow the examples in Europe of bortezomib (Velcade) for multiple myeloma and the interferon-beta drugs for multiple sclerosis: reimbursement is contingent upon patient outcomes. Payers could also create innovative risk-sharing agreements with diagnostics companies. A test could, say, receive conditional, partial reimbursement for a number of years until its clinical effectiveness was definitively demonstrated, when the diagnostics company would be paid in full. The payer would limit cost exposure by covering part of the costs for a limited time; diagnostics companies would benefit from early coverage decisions.\\u003c/p\\u003e\\u003cp\\u003e\\r\\nOver the next few decades, the development of omics sciences (such as genomics) and supporting technologies will enable the creation of more and more personalized-medicine tests. Yet poorly aligned incentives for stakeholders could hamper their use. All stakeholders should therefore work together to reshape these incentives and so reap the benefits of personalized medicine.\\u003cbr\\u003e\\u003c/p\\u003e\"},\"isFullScreenInteractive\":{\"boolValue\":false},\"hideStickySocialShareBar\":{\"boolValue\":false},\"desktopID\":{\"value\":\"\"},\"mobileID\":{\"value\":\"\"},\"desktopURL\":{\"value\":\"\"},\"mobileURL\":{\"value\":\"\"},\"desktopPaddingPercentage\":{\"value\":\"\"},\"mobilePaddingPercentage\":{\"value\":\"\"},\"desktopOverrideHeight\":{\"value\":\"\"},\"mobileOverrideHeight\":{\"value\":\"\"},\"cerosOembedURL\":{\"value\":\"\"},\"cerosRenderMode\":{\"targetItem\":null},\"cerosBackgroundColor\":{\"targetItem\":null},\"hideByLine\":{\"boolValue\":false},\"tableOfContentsTitle\":{\"value\":\"TABLE OF CONTENTS\"},\"accessStatus\":{\"targetItem\":{\"key\":{\"value\":\"RegisteredUsers\"},\"value\":{\"value\":\"Registered Users\"}}},\"articleType\":{\"targetItem\":{\"displayName\":\"Article\"}},\"hasSpecialReport\":{\"boolValue\":false},\"contentType\":{\"targetItem\":{\"displayName\":\"Article\"}},\"sourcePublication\":{\"targetItem\":null},\"externalPublication\":{\"value\":\"\"},\"mobileReady\":{\"boolValue\":true},\"forClientsOnly\":{\"boolValue\":false},\"excludeFromClientLink\":{\"boolValue\":false},\"originalPublishDate\":{\"jsonValue\":{\"value\":\"2010-02-01T00:00:00Z\"}},\"footnotes\":{\"value\":\"\"},\"contributoryPractice\":{\"targetItems\":[]},\"aboutTheAuthors\":{\"value\":\"\\u003cp\\u003e\\u003cstrong\\u003eJerel Davis\\u003c/strong\\u003e is a consultant in McKinseys Silicon Valley office, where \\u003cstrong\\u003eSaumya Sutaria\\u003c/strong\\u003e and \\u003cstrong\\u003eLaura Furstenthal\\u003c/strong\\u003e are principals, and \\u003cstrong\\u003eEdd Fleming\\u003c/strong\\u003e and \\u003cstrong\\u003ePhilip Ma\\u003c/strong\\u003e directors; \\u003cstrong\\u003eAmar Desai\\u003c/strong\\u003e is a consultant in the Los Angeles office; \\u003cstrong\\u003eTroy Norris\\u003c/strong\\u003e is a consultant in the New York office. A version of this article, titled The microeconomics of personalized medicine: todays challenge and tomorrows promise, was first published in \\u003ci\\u003eNature Reviews Drug Discovery\\u003c/i\\u003e, April 2009, Volume 8, No 4, pp. 27986. This article also appeared in \\u003ci\\u003eInvention reinvented\\u003c/i\\u003e, a compendium of articles setting out McKinseys perspectives on pharmaceutical R\\u0026D. To read other articles from the collection, please visit the \\u003ca href=\\\"http://www.mckinsey.com/Client_Service/Pharmaceuticals_and_Medical_Products\\\"\\u003epharmaceutical and medical products\\u003c/a\\u003e section of mckinsey.com. \\u003c/p\\u003e\"},\"authors\":{\"targetItems\":[{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"F5C0E92157434EF4A090FE229AF641C0\",\"name\":\"Jerel Davis\",\"authorTitle\":{\"value\":\"Jerel Davis\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"33A97BF149D64870A79C0F7563FC259C\",\"name\":\"Philip Ma\",\"authorTitle\":{\"value\":\"Philip Ma\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"1A6035B3C03B461F9B579504D978C9B4\",\"name\":\"Author Alias\"},\"authorTitle\":{\"value\":\"Saumya Sutaria\"},\"aliasProfileImage\":{\"alt\":\"\",\"src\":null},\"author\":{\"id\":\"F108649718F84CA3A54AA55930B3AC4B\",\"name\":\"Saum Sutaria\",\"authorTitle\":{\"value\":\"Saum Sutaria\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[{\"standardImage\":{\"src\":\"/~/media/mckinsey/our people/sarun charumilind/sarun_charumilind_standard_profile_1536x1152-v2.jpg\",\"alt\":\"Dr. Sarun Charumilind\"},\"emailLinks\":{\"value\":\"Sarun_Charumilind@McKinsey.com\"},\"linkedInUrl\":{\"value\":\"https://www.linkedin.com/in/sarun-charumilind-651a464\"},\"description\":{\"value\":\"Supports the design and delivery of high-quality, efficient, accessible healthcare that generates the best possible individual and population outcomes through clinically driven, healthcare-value strategy and analytics\"},\"locations\":{\"targetItems\":[{\"name\":\"Philadelphia\",\"displayName\":\"Philadelphia\"}]},\"firmTitle\":{\"value\":\"Partner\"},\"thumbnailImage\":{\"alt\":\"Dr. Sarun Charumilind\",\"src\":\"/~/media/mckinsey/our people/sarun charumilind/sarun_charumilind_headshot_988x741-v2.jpg\"},\"url\":{\"path\":\"/our-people/sarun-charumilind\"}}]}}}]},\"nonPartnerAuthors\":{\"targetItems\":[]},\"interactiveToUse\":{\"targetItem\":null},\"enableArticleComponents\":{\"boolValue\":false},\"relatedArticles\":{\"targetItems\":[{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"New frontiers in pharma R\\u0026D investment\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/new-frontiers-in-pharma-r-and-38d-investment\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"By taking advantage of a range of innovative R\\u0026D financing and partnership models, pharmaceutical companies can place more bets with less money, less work, and less risk.\"},\"standardImage\":{\"src\":null,\"alt\":\"\"},\"heroImage\":null,\"thumbnailImage\":null},{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"R\\u0026amp;D in emerging markets: A new approach for a new era\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/r-and-38d-in-emerging-markets-a-new-approach-for-a-new-era\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"Gone is the time when R\\u0026amp;D in developed markets could meet the pharmaceutical needs of emerging ones. A local presence is required.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/featured insights/emerging markets/r and 38d in emerging markets a new approach for a new era/rdem10_frth.jpg\",\"alt\":\"rdem10_frth\"},\"heroImage\":null,\"thumbnailImage\":null},{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"The road to positive R\\u0026D returns\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/the-road-to-positive-r-and-38d-returns\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"Scientific innovation is not the only route to higher R\\u0026D productivity. Attention to the familiar management areas of cost, speed, and decision making can still reap rewards.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the road to positive r and 38d returns/ropo10_frth.jpg\",\"alt\":\"ropo10_frth\"},\"heroImage\":null,\"thumbnailImage\":null}]},\"useEnhancedAuthors\":{\"boolValue\":false},\"acknowledgements\":{\"value\":\"\"},\"showSocialShareFooter\":{\"boolValue\":false},\"template\":{\"id\":\"683910db-02ba-40ba-92e7-726c880160a9\"},\"hideFromSearchEngines\":{\"boolValue\":false},\"heroFiftyFiftyBackground\":{\"targetItem\":null},\"backgroundColor\":{\"targetItem\":null},\"gradientDirection\":{\"targetItem\":{\"key\":{\"value\":\"Bottom Right\"},\"value\":{\"value\":\"bottom-right\"}}},\"hideStickySubscriptionBar\":{\"value\":false},\"enableRegWall\":{\"boolValue\":false},\"timer\":{\"value\":\"8\"},\"regWallHeading\":{\"value\":\"\"},\"showGoToHomeLink\":{\"boolValue\":true},\"regWallDescription\":{\"value\":\"\"},\"isInsightsStorePage\":{\"boolValue\":false},\"selectedModalSubscriptions\":{\"targetItems\":[]},\"link1\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link2\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link3\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link4\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link5\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"fullReportPDF\":{\"name\":\"Full Report PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"fullReportPDFDisplayName\":{\"value\":\"\"},\"appendixPDF\":{\"name\":\"Appendix PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"appendixPDFDisplayName\":{\"value\":\"\"},\"articlePDF\":{\"name\":\"Article PDF\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/the microeconomics of personalized medicine.pdf\",\"displayName\":\"The microeconomics of personalized medicine\",\"title\":\"\",\"keywords\":\"\",\"description\":\"\",\"extension\":\"pdf\",\"mimeType\":\"application/pdf\",\"size\":509643,\"pageCount\":\"\",\"thumbnailImageSrc\":\"\"},\"briefingNotePDF\":{\"name\":\"Briefing Note PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"discussionPapersPDF\":{\"name\":\"Discussion Papers PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"executiveSummaryPDF\":{\"name\":\"Executive Summary PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"executiveSummaryPDFDisplayName\":{\"value\":\"\"},\"researchPreviewPDF\":{\"name\":\"Research Preview PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"heroImage\":{\"src\":null,\"alt\":\"\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/mipe10_frth.jpg\",\"alt\":\"mipe10_frth\"},\"heroImageTopOffset\":{\"value\":\"\"},\"headerOverlayOpacity\":{\"targetItem\":null},\"heroType\":{\"targetItem\":{\"displayName\":\"Existing\"}},\"photoOverlayOpacity\":{\"targetItem\":null},\"hideHero\":{\"boolValue\":false},\"articleHeroVideoId\":{\"value\":\"\"},\"podcastHeroOmnyAudioID\":{\"value\":\"\"},\"heroBespokeInteractiveID\":{\"value\":\"\"},\"bespokeHeroRenderMode\":{\"targetItem\":null},\"audio\":{\"results\":[]},\"disruptor1up\":{\"results\":[{\"mediaID\":{\"value\":\"cop28\"},\"title\":{\"value\":\"Explore COP28 with McKinsey\"},\"description\":{\"value\":\"Join us for a series of dynamic virtual events during COP28. Discover new research, practical strategies, and collaborations across sectors that propel climate action and growth towards net-zero.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/cop/cop28/cop28-page-thumb_1536x1536.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/sustainability/how-we-help-clients/cop/overview\"}]}}},{\"mediaID\":{\"value\":\"attheedge\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eAt the Edge\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/at-the-edge/id1612870236\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3SnUcezwM20nKnzqvUl6iF\"}]}}},{\"mediaID\":{\"value\":\"authortalks\"},\"title\":{\"value\":\"Visit \\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-books/author-talks\\\"\\u003eAuthor Talks\\u003c/a\\u003e\\u003c/em\\u003e to see the full series.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/author talks/authortalks_1536x1536_v1.png\",\"alt\":\"Author Talks\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/author-talks\"}]}}},{\"mediaID\":{\"value\":\"COVID\"},\"title\":{\"value\":\"Explore McKinseys ongoing coverage of the pandemic\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/risk/our insights/covid 19 implications for business/implications-briefing-note-4-standard-1536x1536.jpg\",\"alt\":\"COVID-19: Implications for business\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more about the business impact of coronavirus and how organizations can respond\",\"Title\":\"\",\"Url\":\"/featured-insights/coronavirus-leading-through-the-crisis\"}]}}},{\"mediaID\":{\"value\":\"CE\"},\"title\":{\"value\":\"Customer experience\"},\"description\":{\"value\":\"More insight into creating competitive advantage by putting customers first and managing their journeys.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/public and social sector/our insights/customer experience/customer-experience_22934010_1536x864.jpg\",\"alt\":\"Customer experience\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"driversofdisruption\"},\"title\":{\"value\":\"Want to subscribe to \\u003ca href=\\\"/features/mckinsey-center-for-future-mobility/our-insights/drivers-of-disruption\\\"\\u003e\\u003cem\\u003eDrivers of Disruption\\u003c/em\\u003e\\u003c/a\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/drivers-of-disruption/id1687257324\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5fWXzWmVKacc5I7u9CQsah?si=KQ-wUOSyQlqcnfexExiH9Q\\u0026nd=1\"}]}}},{\"mediaID\":{\"value\":\"JOL\"},\"title\":{\"value\":\"The Journey of Leadership\"},\"description\":{\"value\":\"\\u003cstrong\\u003eHow CEOs Learn to Lead from the Inside Out\\u003c/strong\\u003e\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/dana-maor\\\"\\u003eDana Maor\\u003c/a\\u003e, \\u003ca href=\\\"https://www.linkedin.com/in/hanswernerkaas\\\"\\u003eHans-Werner Kaas\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/kurt-strovink\\\"\\u003eKurt Strovink\\u003c/a\\u003e, and \\u003ca href=\\\"/our-people/ramesh-srinivasan\\\"\\u003eRamesh Srinivasan\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/journey of leadership/journey-of-leadership-book-cover-1536x1536.jpg\",\"alt\":\"The Journey of Leadership book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/journey-of-leadership\"}]}}},{\"mediaID\":{\"value\":\"surveys\"},\"title\":{\"value\":\"McKinsey\\u0026rsquo;s original survey research\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey global surveys/mck-global-survey-landing-1284442931-thumb-1536x1536.jpg\",\"alt\":\"McKinsey Global Surveys\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-global-surveys\"}]}}},{\"mediaID\":{\"value\":\"healthcarepodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eMcKinsey on Healthcare\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-healthcare/id1469979748\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3y1AgAilV4E5Jz0x4wD9O2?si=mLCTUQ2ORTS_LC5gW_htlA\\u0026dl_branch=1\"}]}}},{\"mediaID\":{\"value\":\"myleadershipjourney\"},\"title\":{\"value\":\"My Leadership Journey\"},\"description\":{\"value\":\"A series of conversations with leaders about the people and experiences that shaped them\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/my leadership journey/my leadership journey collection page_131575496_thumb_1536x1536.jpg\",\"alt\":\"My Leadership Journey\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/my-leadership-journey\"}]}}},{\"mediaID\":{\"value\":\"lessonsfromleaders\"},\"title\":{\"value\":\"State of Organizations: Lessons from leaders\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/state of org lessons from leaders/soo-chapter-2-872507320-standard-1536x1536.jpg\",\"alt\":\"\\\"\\\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore more interviews\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/lessons-from-leaders\"}]}}},{\"mediaID\":{\"value\":\"stateoforg\"},\"title\":{\"value\":\"The State of Organizations 2023\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Report overview\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/the-state-of-organizations-2023\"}]}}},{\"mediaID\":{\"value\":\"titaniumeconomy\"},\"title\":{\"value\":\"The Titanium Economy\"},\"description\":{\"value\":\"How Industrial Technology Can Create a Better, Faster, Stronger America\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/asutosh-padhi\\\"\\u003eAsutosh Padhi\\u003c/a\\u003e, Gaurav Batra, and \\u003ca href=\\\"https://fernweh.com/nick-santhanam/\\\"\\u003eNick Santhanam\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/the titanium economy/titanium_3d-1536x1536-hero-trans.png\",\"alt\":\"The Titanium Economy Book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/the-titanium-economy\"}]}}},{\"mediaID\":{\"value\":\"GII\"},\"title\":{\"value\":\"Global Infrastructure Initiative\"},\"description\":{\"value\":\"Convening global leaders in infrastructure and capital projects in pursuit of new solutions\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the global infrastructure initiative/jpg-cpi-improving-construction-productivity-1536x864.jpg\",\"alt\":\"Improving construction productivity\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"http://www.globalinfrastructureinitiative.com/\"}]}}},{\"mediaID\":{\"value\":\"FOApodcast\"},\"title\":{\"value\":\"Subscribe to \\u003ca href=\\\"/featured-insights/future-of-asia/future-of-asia-podcasts\\\"\\u003e\\u003cem\\u003eFuture of Asia Podcasts\\u003c/em\\u003e\\u003c/a\\u003e\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-asia/id1480316959\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/2CZX4AR2DT4hQCFKJG0cCv?si=B20tkrOmQYymuCUhKCQOwA\"}]}}},{\"mediaID\":{\"value\":\"logisticsdisruptors\"},\"title\":{\"value\":\"Logistics Disruptors\"},\"description\":{\"value\":\"Meet the companies shaping how goods will move tomorrow.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/travel logistics and infrastructure/our insights/logistics disruptors/tli-logistics-disruptors-1536x1536.jpeg\",\"alt\":\"illustration autonomous truck driving off into the future\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/travel-logistics-and-infrastructure/our-insights/logistics-disruptors\"}]}}},{\"mediaID\":{\"value\":\"mckinseyexplainers\"},\"title\":{\"value\":\"Looking for direct answers to other complex questions?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey explainers/mckinseyexplainers-flat-thumb-1536x1536.jpg\",\"alt\":\"Circular, white maze filled with white semicircles.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore the full McKinsey Explainers series\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-explainers\"}]}}},{\"mediaID\":{\"value\":\"livesandlegacies\"},\"title\":{\"value\":\"\\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-lives-and-legacies\\\"\\u003eMcKinsey on Lives \\u0026amp; Legacies\\u003c/a\\u003e\\u003c/em\\u003e\"},\"description\":{\"value\":\"Highlighting the lasting impact of leaders and executives\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey on lives and legacies/lives-and-legacies-landing-page-thumb-1536x1536.jpg\",\"alt\":\"McKinsey on Lives \\u0026 Legacies\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore previous obituaries\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-lives-and-legacies\"}]}}},{\"mediaID\":{\"value\":\"Strategy\"},\"title\":{\"value\":\"Strategy in a digital age\"},\"description\":{\"value\":\"Our series on developing corporate and business-unit strategies in a digitally disrupted world.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/our insights/strategy in a digital age/digital-strategy_1536x864_flexpromoimage.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/featured-insights/strategy-in-a-digital-age\"}]}}},{\"mediaID\":{\"value\":\"great\"},\"title\":{\"value\":\"The great re-make: Manufacturing for modern times\"},\"description\":{\"value\":\"This 21-article compendium gives practical insights for manufacturing leaders looking to keep a step ahead of today\\u0026rsquo;s disruptions.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the great remake manufacturing for modern times/jpg-ops-dm-compendium-cover-1536x864.jpg\",\"alt\":\"The great re-make: Manufacturing for modern times\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/capabilities/operations/our-insights/the-great-re-make-manufacturing-for-modern-times-compendium\"}]}}},{\"mediaID\":{\"value\":\"futureofamerica\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eFuture of America\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-america/id1616517376\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/0FpeyjojJTKf2hVtQ3otah\"}]}}},{\"mediaID\":{\"value\":\"governmentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Government\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-government/id1573645359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/61XsO4B2ersroMft8t3KSq\"}]}}},{\"mediaID\":{\"value\":\"podcast\"},\"title\":{\"value\":\"Want to subscribe to the McKinsey Podcast?\\n\"},\"description\":{\"value\":\"\\u003cdiv class=\\\"cta-container -align-horizontal\\\"\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eGoogle Play\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eiTunes\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eStitcher\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn mck-rss-icon\\\"\\u003eRSS\\u003c/a\\u003e\\n\\u003c/div\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[]}}},{\"mediaID\":{\"value\":\"operationspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Operations\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-operations/id1598128813\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/7LYQS2fxAoBmC3LgFNJbi8\"}]}}},{\"mediaID\":{\"value\":\"energyinsights\"},\"title\":{\"value\":\"Speak to an expert about our upstream capabilities\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/oil and gas/how we help clients/energy insights/newsletter-signup-promo-bar-1536x768.jpg\",\"alt\":\"EI newsletter sign up\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"buildingproductspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Building Products\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-building-product/id1735607317\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/79pncGJtBtzz7pFoR6OiH8\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/how-we-help-clients/mckinsey-academy/product-academy/mckinsey-on-building-product\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Talent\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-talent/id1491112396\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5sW4eHEFMbOvAFJjMfN9a6\"}]}}},{\"mediaID\":{\"value\":\"outlook\"},\"title\":{\"value\":\"A longer, more comprehensive version of our Global Oil Supply \\u0026 Demand Outlook is available for purchase upon request.\\n\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast2\"},\"title\":{\"value\":\"McKinsey Talks Talent Podcast\"},\"description\":{\"value\":\"Bryan Hancock, Brooke Weddle, and other talent experts help you navigate a fast-changing landscape and prepare for the future of work by making talent a competitive advantage.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/mckinsey talks talent/mck-mtt-disruptor-full-1536x864-smoke-may-2021.jpg\",\"alt\":\"McKinsey Talks Talent\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"See more episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/mckinsey-talks-talent-podcast\"}]}}},{\"mediaID\":{\"value\":\"investing\"},\"title\":{\"value\":\"Subscribe to McKinsey on Investing\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/private-capital/our-insights/mckinsey-on-investing-issue-1/contact\"}]}}},{\"mediaID\":{\"value\":\"women matter\"},\"title\":{\"value\":\"Subscribe to McKinsey \\u003cem\\u003eWomen Matter Canada\\u003c/em\\u003e\"},\"description\":{\"value\":\"Please subscribe if your organization is interested in learning about participating in future research.\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"customs\"},\"title\":{\"value\":\"This article was written as part of a larger research effort to identify opportunities for improvement and innovation at customs agencies globally.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/public-sector/our-insights/contact\"}]}}},{\"mediaID\":{\"value\":\"tech\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eCreating value beyond the hype\\u003c/span\\u003e\"},\"description\":{\"value\":\"Let\\u0026rsquo;s deliver on the promise of technology from strategy to scale.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/how we help clients/2024/never-just-tech_thumb_1536x1536.jpg\",\"alt\":\"Never just tech\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/mckinsey-digital/how-we-help-clients?cid=njt-ste-crk-mbm-mbm--2403-promo01-njt-bam-web\"}]}}},{\"mediaID\":{\"value\":\"sust\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eMove from plans to progress.\\u003c/span\\u003e\"},\"description\":{\"value\":\"Sustainability matters. Together well make it real.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/sustainability-campaign_promo-thumb_1536x1536.jpg\",\"alt\":\"Move from plans to progress.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/sustainability/how-we-help-clients/?cid=susti24-ste-crk-mbm-m01-other-glb-web\"}]}}},{\"mediaID\":{\"value\":\"nwowpodcast\"},\"title\":{\"value\":\"Subscribe to the New World of Work podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-new-world-of-work/id1319502839?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI\"}]}}},{\"mediaID\":{\"value\":\"globalpodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eThe McKinsey Podcast\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-mckinsey-podcast/id285260960?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4dyjRTP9xzEUPgleo6XjXI\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"YouTube\",\"Title\":\"\",\"Url\":\"https://www.youtube.com/@McKinsey/podcasts\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-podcast\"}]}}},{\"mediaID\":{\"value\":\"Qaudio\"},\"title\":{\"value\":\"Discover and subscribe to McKinsey Quarterly Audio\"},\"description\":{\"value\":\"\\u003cstrong\\u003eFive ways to subscribe:\\u003c/strong\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/mckinsey-quarterly-audio/id1437925222?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5mb2zYJnrPcRrML8gx5doD\"}]}}},{\"mediaID\":{\"value\":\"shortlist\"},\"title\":{\"value\":\"Subscribe to the Shortlist\"},\"description\":{\"value\":\"McKinsey\\u0026rsquo;s new weekly newsletter, featuring must-read content on a range of topics, every Friday\"},\"image\":{\"src\":\"/~/media/mckinsey/email/shortlist/template/shortlist_promo-interrupter-849120982_1536x1536.jpg\",\"alt\":\"the Shortlist\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Get the Shortlist in your inbox\",\"Title\":\"\",\"Url\":\"/user-registration/manage-account/edit-subscriptions\"}]}}},{\"mediaID\":{\"value\":\"retailpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Consumer and Retail\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-consumer-and-retail/id1526250428\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/41D4bro8PPDOGhEgOEJyHB?si=7l3SeYCZQD-7v3toqd9fHQ\"}]}}},{\"mediaID\":{\"value\":\"insurancepodcast\"},\"title\":{\"value\":\"Want to subscribe to the \\u003cem\\u003eMcKinsey on Insurance\\u003c/em\\u003e podcast?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-insurance/id1533196359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5gZ6YKF7n7C9zWaER4mFZ5\"}]}}},{\"mediaID\":{\"value\":\"strategypodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eInside the Strategy Room\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/inside-the-strategy-room/id1422814215?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4TcFfiQ0e6OYuc5kRDLxqj\"}]}}},{\"mediaID\":{\"value\":\"mgipodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eForward Thinking\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/forward-thinking/id1319502839\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI?si=0zvPmiCsQ7SBAPanfpY4aA\\u0026nd=1\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/mgi/forward-thinking\"}]}}}]},\"globalDisruptors\":{\"disruptor1up\":{\"results\":[{\"mediaID\":{\"value\":\"cop28\"},\"title\":{\"value\":\"Explore COP28 with McKinsey\"},\"description\":{\"value\":\"Join us for a series of dynamic virtual events during COP28. Discover new research, practical strategies, and collaborations across sectors that propel climate action and growth towards net-zero.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/cop/cop28/cop28-page-thumb_1536x1536.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/sustainability/how-we-help-clients/cop/overview\"}]}}},{\"mediaID\":{\"value\":\"attheedge\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eAt the Edge\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/at-the-edge/id1612870236\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3SnUcezwM20nKnzqvUl6iF\"}]}}},{\"mediaID\":{\"value\":\"authortalks\"},\"title\":{\"value\":\"Visit \\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-books/author-talks\\\"\\u003eAuthor Talks\\u003c/a\\u003e\\u003c/em\\u003e to see the full series.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/author talks/authortalks_1536x1536_v1.png\",\"alt\":\"Author Talks\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/author-talks\"}]}}},{\"mediaID\":{\"value\":\"COVID\"},\"title\":{\"value\":\"Explore McKinseys ongoing coverage of the pandemic\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/risk/our insights/covid 19 implications for business/implications-briefing-note-4-standard-1536x1536.jpg\",\"alt\":\"COVID-19: Implications for business\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more about the business impact of coronavirus and how organizations can respond\",\"Title\":\"\",\"Url\":\"/featured-insights/coronavirus-leading-through-the-crisis\"}]}}},{\"mediaID\":{\"value\":\"CE\"},\"title\":{\"value\":\"Customer experience\"},\"description\":{\"value\":\"More insight into creating competitive advantage by putting customers first and managing their journeys.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/public and social sector/our insights/customer experience/customer-experience_22934010_1536x864.jpg\",\"alt\":\"Customer experience\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"driversofdisruption\"},\"title\":{\"value\":\"Want to subscribe to \\u003ca href=\\\"/features/mckinsey-center-for-future-mobility/our-insights/drivers-of-disruption\\\"\\u003e\\u003cem\\u003eDrivers of Disruption\\u003c/em\\u003e\\u003c/a\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/drivers-of-disruption/id1687257324\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5fWXzWmVKacc5I7u9CQsah?si=KQ-wUOSyQlqcnfexExiH9Q\\u0026nd=1\"}]}}},{\"mediaID\":{\"value\":\"JOL\"},\"title\":{\"value\":\"The Journey of Leadership\"},\"description\":{\"value\":\"\\u003cstrong\\u003eHow CEOs Learn to Lead from the Inside Out\\u003c/strong\\u003e\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/dana-maor\\\"\\u003eDana Maor\\u003c/a\\u003e, \\u003ca href=\\\"https://www.linkedin.com/in/hanswernerkaas\\\"\\u003eHans-Werner Kaas\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/kurt-strovink\\\"\\u003eKurt Strovink\\u003c/a\\u003e, and \\u003ca href=\\\"/our-people/ramesh-srinivasan\\\"\\u003eRamesh Srinivasan\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/journey of leadership/journey-of-leadership-book-cover-1536x1536.jpg\",\"alt\":\"The Journey of Leadership book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/journey-of-leadership\"}]}}},{\"mediaID\":{\"value\":\"surveys\"},\"title\":{\"value\":\"McKinsey\\u0026rsquo;s original survey research\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey global surveys/mck-global-survey-landing-1284442931-thumb-1536x1536.jpg\",\"alt\":\"McKinsey Global Surveys\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-global-surveys\"}]}}},{\"mediaID\":{\"value\":\"healthcarepodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eMcKinsey on Healthcare\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-healthcare/id1469979748\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3y1AgAilV4E5Jz0x4wD9O2?si=mLCTUQ2ORTS_LC5gW_htlA\\u0026dl_branch=1\"}]}}},{\"mediaID\":{\"value\":\"myleadershipjourney\"},\"title\":{\"value\":\"My Leadership Journey\"},\"description\":{\"value\":\"A series of conversations with leaders about the people and experiences that shaped them\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/my leadership journey/my leadership journey collection page_131575496_thumb_1536x1536.jpg\",\"alt\":\"My Leadership Journey\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/my-leadership-journey\"}]}}},{\"mediaID\":{\"value\":\"lessonsfromleaders\"},\"title\":{\"value\":\"State of Organizations: Lessons from leaders\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/state of org lessons from leaders/soo-chapter-2-872507320-standard-1536x1536.jpg\",\"alt\":\"\\\"\\\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore more interviews\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/lessons-from-leaders\"}]}}},{\"mediaID\":{\"value\":\"stateoforg\"},\"title\":{\"value\":\"The State of Organizations 2023\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Report overview\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/the-state-of-organizations-2023\"}]}}},{\"mediaID\":{\"value\":\"titaniumeconomy\"},\"title\":{\"value\":\"The Titanium Economy\"},\"description\":{\"value\":\"How Industrial Technology Can Create a Better, Faster, Stronger America\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/asutosh-padhi\\\"\\u003eAsutosh Padhi\\u003c/a\\u003e, Gaurav Batra, and \\u003ca href=\\\"https://fernweh.com/nick-santhanam/\\\"\\u003eNick Santhanam\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/the titanium economy/titanium_3d-1536x1536-hero-trans.png\",\"alt\":\"The Titanium Economy Book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/the-titanium-economy\"}]}}},{\"mediaID\":{\"value\":\"GII\"},\"title\":{\"value\":\"Global Infrastructure Initiative\"},\"description\":{\"value\":\"Convening global leaders in infrastructure and capital projects in pursuit of new solutions\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the global infrastructure initiative/jpg-cpi-improving-construction-productivity-1536x864.jpg\",\"alt\":\"Improving construction productivity\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"http://www.globalinfrastructureinitiative.com/\"}]}}},{\"mediaID\":{\"value\":\"FOApodcast\"},\"title\":{\"value\":\"Subscribe to \\u003ca href=\\\"/featured-insights/future-of-asia/future-of-asia-podcasts\\\"\\u003e\\u003cem\\u003eFuture of Asia Podcasts\\u003c/em\\u003e\\u003c/a\\u003e\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-asia/id1480316959\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/2CZX4AR2DT4hQCFKJG0cCv?si=B20tkrOmQYymuCUhKCQOwA\"}]}}},{\"mediaID\":{\"value\":\"logisticsdisruptors\"},\"title\":{\"value\":\"Logistics Disruptors\"},\"description\":{\"value\":\"Meet the companies shaping how goods will move tomorrow.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/travel logistics and infrastructure/our insights/logistics disruptors/tli-logistics-disruptors-1536x1536.jpeg\",\"alt\":\"illustration autonomous truck driving off into the future\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/travel-logistics-and-infrastructure/our-insights/logistics-disruptors\"}]}}},{\"mediaID\":{\"value\":\"mckinseyexplainers\"},\"title\":{\"value\":\"Looking for direct answers to other complex questions?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey explainers/mckinseyexplainers-flat-thumb-1536x1536.jpg\",\"alt\":\"Circular, white maze filled with white semicircles.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore the full McKinsey Explainers series\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-explainers\"}]}}},{\"mediaID\":{\"value\":\"livesandlegacies\"},\"title\":{\"value\":\"\\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-lives-and-legacies\\\"\\u003eMcKinsey on Lives \\u0026amp; Legacies\\u003c/a\\u003e\\u003c/em\\u003e\"},\"description\":{\"value\":\"Highlighting the lasting impact of leaders and executives\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey on lives and legacies/lives-and-legacies-landing-page-thumb-1536x1536.jpg\",\"alt\":\"McKinsey on Lives \\u0026 Legacies\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore previous obituaries\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-lives-and-legacies\"}]}}},{\"mediaID\":{\"value\":\"Strategy\"},\"title\":{\"value\":\"Strategy in a digital age\"},\"description\":{\"value\":\"Our series on developing corporate and business-unit strategies in a digitally disrupted world.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/our insights/strategy in a digital age/digital-strategy_1536x864_flexpromoimage.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/featured-insights/strategy-in-a-digital-age\"}]}}},{\"mediaID\":{\"value\":\"great\"},\"title\":{\"value\":\"The great re-make: Manufacturing for modern times\"},\"description\":{\"value\":\"This 21-article compendium gives practical insights for manufacturing leaders looking to keep a step ahead of today\\u0026rsquo;s disruptions.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the great remake manufacturing for modern times/jpg-ops-dm-compendium-cover-1536x864.jpg\",\"alt\":\"The great re-make: Manufacturing for modern times\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/capabilities/operations/our-insights/the-great-re-make-manufacturing-for-modern-times-compendium\"}]}}},{\"mediaID\":{\"value\":\"futureofamerica\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eFuture of America\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-america/id1616517376\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/0FpeyjojJTKf2hVtQ3otah\"}]}}},{\"mediaID\":{\"value\":\"governmentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Government\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-government/id1573645359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/61XsO4B2ersroMft8t3KSq\"}]}}},{\"mediaID\":{\"value\":\"podcast\"},\"title\":{\"value\":\"Want to subscribe to the McKinsey Podcast?\\n\"},\"description\":{\"value\":\"\\u003cdiv class=\\\"cta-container -align-horizontal\\\"\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eGoogle Play\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eiTunes\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eStitcher\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn mck-rss-icon\\\"\\u003eRSS\\u003c/a\\u003e\\n\\u003c/div\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[]}}},{\"mediaID\":{\"value\":\"operationspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Operations\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-operations/id1598128813\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/7LYQS2fxAoBmC3LgFNJbi8\"}]}}},{\"mediaID\":{\"value\":\"energyinsights\"},\"title\":{\"value\":\"Speak to an expert about our upstream capabilities\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/oil and gas/how we help clients/energy insights/newsletter-signup-promo-bar-1536x768.jpg\",\"alt\":\"EI newsletter sign up\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"buildingproductspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Building Products\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-building-product/id1735607317\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/79pncGJtBtzz7pFoR6OiH8\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/how-we-help-clients/mckinsey-academy/product-academy/mckinsey-on-building-product\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Talent\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-talent/id1491112396\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5sW4eHEFMbOvAFJjMfN9a6\"}]}}},{\"mediaID\":{\"value\":\"outlook\"},\"title\":{\"value\":\"A longer, more comprehensive version of our Global Oil Supply \\u0026 Demand Outlook is available for purchase upon request.\\n\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast2\"},\"title\":{\"value\":\"McKinsey Talks Talent Podcast\"},\"description\":{\"value\":\"Bryan Hancock, Brooke Weddle, and other talent experts help you navigate a fast-changing landscape and prepare for the future of work by making talent a competitive advantage.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/mckinsey talks talent/mck-mtt-disruptor-full-1536x864-smoke-may-2021.jpg\",\"alt\":\"McKinsey Talks Talent\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"See more episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/mckinsey-talks-talent-podcast\"}]}}},{\"mediaID\":{\"value\":\"investing\"},\"title\":{\"value\":\"Subscribe to McKinsey on Investing\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/private-capital/our-insights/mckinsey-on-investing-issue-1/contact\"}]}}},{\"mediaID\":{\"value\":\"women matter\"},\"title\":{\"value\":\"Subscribe to McKinsey \\u003cem\\u003eWomen Matter Canada\\u003c/em\\u003e\"},\"description\":{\"value\":\"Please subscribe if your organization is interested in learning about participating in future research.\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"customs\"},\"title\":{\"value\":\"This article was written as part of a larger research effort to identify opportunities for improvement and innovation at customs agencies globally.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/public-sector/our-insights/contact\"}]}}},{\"mediaID\":{\"value\":\"tech\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eCreating value beyond the hype\\u003c/span\\u003e\"},\"description\":{\"value\":\"Let\\u0026rsquo;s deliver on the promise of technology from strategy to scale.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/how we help clients/2024/never-just-tech_thumb_1536x1536.jpg\",\"alt\":\"Never just tech\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/mckinsey-digital/how-we-help-clients?cid=njt-ste-crk-mbm-mbm--2403-promo01-njt-bam-web\"}]}}},{\"mediaID\":{\"value\":\"sust\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eMove from plans to progress.\\u003c/span\\u003e\"},\"description\":{\"value\":\"Sustainability matters. Together well make it real.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/sustainability-campaign_promo-thumb_1536x1536.jpg\",\"alt\":\"Move from plans to progress.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/sustainability/how-we-help-clients/?cid=susti24-ste-crk-mbm-m01-other-glb-web\"}]}}},{\"mediaID\":{\"value\":\"nwowpodcast\"},\"title\":{\"value\":\"Subscribe to the New World of Work podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-new-world-of-work/id1319502839?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI\"}]}}},{\"mediaID\":{\"value\":\"globalpodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eThe McKinsey Podcast\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-mckinsey-podcast/id285260960?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4dyjRTP9xzEUPgleo6XjXI\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"YouTube\",\"Title\":\"\",\"Url\":\"https://www.youtube.com/@McKinsey/podcasts\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-podcast\"}]}}},{\"mediaID\":{\"value\":\"Qaudio\"},\"title\":{\"value\":\"Discover and subscribe to McKinsey Quarterly Audio\"},\"description\":{\"value\":\"\\u003cstrong\\u003eFive ways to subscribe:\\u003c/strong\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/mckinsey-quarterly-audio/id1437925222?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5mb2zYJnrPcRrML8gx5doD\"}]}}},{\"mediaID\":{\"value\":\"shortlist\"},\"title\":{\"value\":\"Subscribe to the Shortlist\"},\"description\":{\"value\":\"McKinsey\\u0026rsquo;s new weekly newsletter, featuring must-read content on a range of topics, every Friday\"},\"image\":{\"src\":\"/~/media/mckinsey/email/shortlist/template/shortlist_promo-interrupter-849120982_1536x1536.jpg\",\"alt\":\"the Shortlist\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Get the Shortlist in your inbox\",\"Title\":\"\",\"Url\":\"/user-registration/manage-account/edit-subscriptions\"}]}}},{\"mediaID\":{\"value\":\"retailpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Consumer and Retail\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-consumer-and-retail/id1526250428\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/41D4bro8PPDOGhEgOEJyHB?si=7l3SeYCZQD-7v3toqd9fHQ\"}]}}},{\"mediaID\":{\"value\":\"insurancepodcast\"},\"title\":{\"value\":\"Want to subscribe to the \\u003cem\\u003eMcKinsey on Insurance\\u003c/em\\u003e podcast?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-insurance/id1533196359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5gZ6YKF7n7C9zWaER4mFZ5\"}]}}},{\"mediaID\":{\"value\":\"strategypodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eInside the Strategy Room\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/inside-the-strategy-room/id1422814215?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4TcFfiQ0e6OYuc5kRDLxqj\"}]}}},{\"mediaID\":{\"value\":\"mgipodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eForward Thinking\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/forward-thinking/id1319502839\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI?si=0zvPmiCsQ7SBAPanfpY4aA\\u0026nd=1\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/mgi/forward-thinking\"}]}}}]},\"disruptorsignup\":{\"results\":[{\"mediaID\":{\"value\":\"full-width\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"fullwidth\"},\"value\":{\"value\":\"Full Width\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}},{\"mediaID\":{\"value\":\"left\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"left\"},\"value\":{\"value\":\"Left\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}}]}},\"ceros\":{\"results\":[]},\"exhibit\":{\"results\":[{\"id\":\"A4409BF1182343D8B9CEAA0F52F082D0\",\"displayName\":\"Exhibit 1\",\"mediaID\":{\"value\":\"1\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"Not all diagnostic tests cut costs for payers.\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"Exhibit\"}},\"displayNumber\":{\"value\":\"1\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Web_MicroeconMedicine_ex1\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/svgz_web_microeconmedicine_ex1.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/png_web_microeconmedicine_ex1.png\",\"alt\":\"Web_MicroeconMedicine_ex1\"},\"height\":{\"value\":\"986\"},\"width\":{\"value\":\"1779\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}},{\"id\":\"9ACF515B56624D30867389FC0547178B\",\"displayName\":\"Exhibit 2\",\"mediaID\":{\"value\":\"2\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"Markers for prevention are least cost effective for programs with high patient turnover.\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"Exhibit\"}},\"displayNumber\":{\"value\":\"2\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Web_MicroeconMedicine_ex2\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/svgz_web_microeconmedicine_ex2.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/png_web_microeconmedicine_ex2.png\",\"alt\":\"Web_MicroeconMedicine_ex2\"},\"height\":{\"value\":\"1051\"},\"width\":{\"value\":\"1775\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}},{\"id\":\"15C3E18B1A5C4768B1C78872C67710DE\",\"displayName\":\"Exhibit 3\",\"mediaID\":{\"value\":\"3\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"The potential to generate greater value after marketing is vastly more important for the economics of pharmaceutical and biotechnology companies than making development more productive.\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"Exhibit\"}},\"displayNumber\":{\"value\":\"3\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Web_MicroeconMedicine_ex3\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/svgz_web_microeconmedicine_ex3.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/png_web_microeconmedicine_ex3.png\",\"alt\":\"Web_MicroeconMedicine_ex3\"},\"height\":{\"value\":\"644\"},\"width\":{\"value\":\"1779\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}},{\"id\":\"B973A4872C3F45BEA07C7D58A8ECF9E7\",\"displayName\":\"Exhibit 4\",\"mediaID\":{\"value\":\"4\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"Companies are likely to invest in areas with the highest potential rewards.\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"Exhibit\"}},\"displayNumber\":{\"value\":\"4\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Web_MicroeconMedicine_ex4\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/svgz_web_microeconmedicine_ex4.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/png_web_microeconmedicine_ex4.png\",\"alt\":\"Web_MicroeconMedicine_ex4\"},\"height\":{\"value\":\"951\"},\"width\":{\"value\":\"1597\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}},{\"id\":\"D734BDFF22224754A3DFFC8CCBC74B8F\",\"displayName\":\"Exhibit 5\",\"mediaID\":{\"value\":\"5\"},\"includeTheAccessibilityDisclaimerText\":{\"boolValue\":true},\"headline\":{\"jsonValue\":{\"value\":\"The molecular-diagnostics business case still holds significant risk.\"}},\"hideBottomBorder\":{\"boolValue\":false},\"hideEyebrow\":{\"boolValue\":false},\"eyebrow\":{\"jsonValue\":{\"value\":\"Exhibit \"}},\"displayNumber\":{\"value\":\"5\"},\"description\":{\"jsonValue\":{\"value\":\"\"}},\"desktopImage\":{\"alt\":\"Web_MicroeconMedicine_ex5\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/svgz_web_microeconmedicine_ex5.svgz\",\"description\":\"\"},\"mobileImage\":{\"alt\":\"\",\"src\":null},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Medium content column width\"},\"value\":{\"value\":\"medium\"}}},\"flourishDataVisualizationID\":{\"value\":\"\"},\"pNGImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/the microeconomics of personalized medicine/png_web_microeconmedicine_ex5.png\",\"alt\":\"Web_MicroeconMedicine_ex5\"},\"height\":{\"value\":\"978\"},\"width\":{\"value\":\"1779\"},\"mobileSVGImage\":{\"src\":null,\"alt\":\"\"},\"mobilePNGImage\":{\"src\":null,\"alt\":\"\"}}]},\"image\":{\"results\":[]},\"exhibitcarousel\":{\"results\":[]},\"pullquote\":{\"results\":[]},\"disruptorsignup\":{\"results\":[{\"mediaID\":{\"value\":\"full-width\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"fullwidth\"},\"value\":{\"value\":\"Full Width\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}},{\"mediaID\":{\"value\":\"left\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"left\"},\"value\":{\"value\":\"Left\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}}]},\"articlesidebar\":{\"results\":[]},\"globalsidebar\":{\"results\":[]},\"video\":{\"results\":[]},\"scrollycontainer\":{\"results\":[]},\"bespokeinteractive\":{\"results\":[]},\"storycontainer\":{\"results\":[]},\"interactive\":{\"results\":[]},\"sectionheader\":{\"results\":[]},\"statementdisruptor\":{\"results\":[]},\"fullbleedphoto\":{\"results\":[]},\"tocitem\":{\"results\":[]},\"quizcontainer\":{\"results\":[]},\"generalup\":{\"results\":[]},\"twoupmedium\":{\"results\":[]},\"accordion\":{\"results\":[]},\"factoid\":{\"results\":[]},\"promobarwithquote\":{\"results\":[]},\"oneupmedium\":{\"results\":[]},\"oneupmediumquote\":{\"results\":[]},\"gridwall\":{\"results\":[]},\"twoupsmall\":{\"results\":[]},\"oneclicksubscribe\":{\"results\":[]},\"promobar\":{\"results\":[]},\"promobanner\":{\"results\":[]},\"sectionhero\":{\"results\":[]},\"threeuplinklist\":{\"results\":[]},\"table\":{\"results\":[]},\"isFiveFiftyHorizontalArticle\":{\"boolValue\":false},\"fiveFifty\":{\"results\":[]}},\"contextItem\":{\"ancestors\":[{\"breadCrumbUrl\":{\"path\":\"/industries/life-sciences/our-insights\"},\"breadCrumbTitle\":{\"value\":\"Our Insights\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Insights on Life Sciences\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}},{\"breadCrumbUrl\":{\"path\":\"/industries/life-sciences/how-we-help-clients\"},\"breadCrumbTitle\":null,\"isMiniSite\":{\"boolValue\":true},\"displayName\":\"Life Sciences\",\"template\":{\"id\":\"414C6C64AD35440E9668CF39D8A18CCF\"}},{\"breadCrumbUrl\":{\"path\":\"/industries\"},\"breadCrumbTitle\":{\"value\":\"Industries\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Industries\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}},{\"breadCrumbUrl\":{\"path\":\"/\"},\"breadCrumbTitle\":{\"value\":\"\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Home\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}}]}}},\"placeholders\":{\"main-area\":[],\"sidebar-area\":[]}}]}},\"itemId\":\"1b13b0b4-89b5-4f5c-b948-ee5f5e9463cb\",\"pageEditing\":false,\"site\":{\"name\":\"website\"},\"pageState\":\"normal\",\"language\":\"en\",\"pageMetaData\":{\"alternateLanguages\":[{\"languageCode\":\"en\",\"displayName\":\"English\",\"url\":\"/industries/life-sciences/our-insights/the-microeconomics-of-personalized-medicine\"}],\"currentLanguage\":\"en\",\"navigationLink\":\"industries\",\"activeItemId\":\"{BB8498AC-8CC4-4BFB-8832-53C76F3E61CF}\",\"miniSiteId\":\"{CDBF3A89-AE60-459E-ACF8-786E31307534}\",\"officeCode\":\"\",\"officeDisplayName\":\"\",\"subscriptionPracticeData\":null,\"isAlaisedPage\":false,\"originalHostName\":\"www.mckinsey.com\",\"updatedDate\":\"2023-02-25T08:51:17Z\",\"createdDate\":\"2012-05-10T04:15:54Z\",\"practice\":{\"isDefaultPractice\":false,\"name\":\"Life Sciences\",\"code\":\"N20\",\"stickyTitle\":\"Sign up for emails on new Life Sciences articles\",\"stickySubtitle\":\"Never miss an insight. We'll email you when new articles are published on this topic.\",\"previewLink\":\"\",\"previewLinkLabel\":\"Preview\",\"description\":null,\"descriptionText\":\"Get the latest articles on this topic delivered to your inbox\",\"frequency\":\"Alert\",\"regFormTitle\":null},\"url\":\"/industries/life-sciences/our-insights/the-microeconomics-of-personalized-medicine\",\"isCareersPage\":false,\"officePath\":\"\",\"hideAppPromo\":false,\"itemInfo\":{\"id\":\"1b13b0b4-89b5-4f5c-b948-ee5f5e9463cb\",\"fullPath\":\"/sitecore/content/McKinsey/Home/Industries/Life Sciences/Our Insights/The microeconomics of personalized medicine\",\"templateName\":\"ArticleJSS\",\"templateID\":\"683910db-02ba-40ba-92e7-726c880160a9\"}},\"defaultSettings\":{\"McKinsey Quarterly\":\"\\u003cem\\u003eMcKinsey Quarterly\\u003c/em\\u003e\",\"FacebookCID\":\"soc-web\",\"LinkedInCID\":\"soc-web\",\"TwitterCID\":\"soc-web\",\"Home Page SEO Details\":{\"Description\":\"McKinsey \\u0026 Company is the trusted advisor and counselor to many of the world's most influential businesses and institutions.\",\"Image_Url\":\"/~/media/images/global/seoimageplaceholder.jpg\",\"Image_Alt\":\"\"}},\"alumniDatalayerChunk\":\"static/chunks/alumnidatalayer.2eb8cbe055d39895.js\"},\"componentProps\":{},\"notFound\":false,\"noAccess\":false},\"__N_PREVIEW\":true,\"__N_SSP\":true},\"page\":\"/[[...path]]\",\"query\":{\"timestamp\":\"1729764549989\",\"path\":[\"featured-insights\",\"employment-and-growth\",\"the-looming-deleveraging-challenge\"]},\"buildId\":\"AymXir4ImcRSnB3UIpSL6\",\"runtimeConfig\":{\"CONFIG_ENV\":\"production\",\"CURRENT_ENV\":\"production\",\"PUBLIC_URL\":\"https://www.mckinsey.com\",\"PUBLIC_CMS_URL\":\"https://cms-prod.mckinsey.com\",\"RECAPTCHA_V3_KEY\":\"6LdC5twSAAAAAF0dePIbY_ckeF05mKdYYJXn7uTg\",\"INVISIBLE_RECAPTCHA_KEY\":\"6LcWCs0UAAAAAEik2NaGkfGH8mGHo1ThxIt-qUoE\",\"USER_SERVICE_API_HOST\":\"https://prd-api.mckinsey.com\",\"MOBILE_SERVICES_HOST\":\"https://mobileservices.mckinsey.com\",\"SEARCH_SERVICE_API_HOST\":\"https://mckapi.mckinsey.com\",\"OT_DATA_DOMAIN_SCRIPT_COM\":\"915b5091-0d7e-44d2-a8c4-cf08267e52fe\",\"OT_DATA_DOMAIN_SCRIPT_DE\":\"13f50396-9d33-4d95-ba3e-1f108fa91009\",\"OT_DATA_DOMAIN_SCRIPT_BR\":\"679eae24-1d5c-4f33-8aae-b35aa8269966\",\"ADOBE_LAUNCH\":\"a400cfbb2fd3\",\"BCOV_POLICY\":\"BCpkADawqM3Xn1B8iTmHawNytUSk0kXaQKMSM51CBVsYKHfwlRhZimTJqbOOq0NuyxTKQnvb4V9myMVRjwGkyGtJQO2HrUPOJHcsgkpbB-jyHwswonskf6XnZaF0TyyKkAQgbymSMtudeD9CLk-xCpqAzTaNUm7a3M3QKLN4pdLRNJ9_HbVMWzNpiUr5ezAVdMciDMwsD-gxNl43d7bfVP3wRhTNWbWUYn3WK7-Oz2gbxV6mMTm0jJU3SjK_x0meTprYUgdUWA-iDgwVglsnfJ_SVtVDPZypUokKv85GzFLM-ywjWlPM2Hg1ucemwwOpa-qvYBGfeMV7zP3n6s22hFCBveiWtHEBpV9N8f4rjmunMlxBx7kSlxIRjWquZm70hLRXMoxAgQ22BC86tBhgR_d1l9_-FzZuZIlZhzJwJi3ug1HszooHM8uEMOkHmB5nYj5XEgVk5JFYGcSwFSnMnNzE1ej2J3jcEiE3eSWHcremWjCZ0s9bs_8R08WpGWkBp8WMXUFfmhPBMk-MGixR_yIu7nJ6B_hYBnVhqKnnoW-xxEmRxgwG0Ev0S96cAcBG8qdlChGN7o1qN0heGTUIYnDk703q3lt9j7X4FgaITrlcPZOWZ96EHytVKUAtmtVp5BVGpiLn4viuUpEdAM_CLSBIaPVunk-39L8tm6m8iUYmbMX_KXPyaL900bQtVQgK39FCa0pUEZ_jSBOGNj1FH8NUPN2TS8_csNWfpN7gsaD9FBN3wUtawAD_RPdJ952odfwJqyvrkN89AyKnFdFMvUh6_4LCIQVYd4M5KC_k1WNLYb11KZhq6O4UaoyD4X1pV4-x0jBzEnc4VQTkL_04dw2xdPJ1uqUrmHuUcIBO0SKaEk6_5HYc3GKfYwmPz1oxMpOi-Rzw1QPyWIdbrcZdFbIHoVZ8FKfyslEv392pJMiKzUnVWL_3mZ0UqnGtddwlXYVdSs57AUdlrfOe7TVaaIMZ_kL7FSrbWrsaSufitSYr62xD1K1-qeb4wkx8QQEorxGJ3RG1Vpn97Pn5JEC_jvj0s7uzFgidYR9bp80EMmPCHUmRg-Hm1Aq1B4YMNc1ARnFz6UvT_8_pMhJEwKuypA-nPoJu4JZJNLVUdw\",\"sitecoreApiKey\":\"{AD59BE63-BA20-47D4-A1B0-ECF30588E2E2}\",\"sitecoreApiHost\":\"https://prod.mckinsey.com\",\"FB_APP_ID\":\"1382278882079245\",\"ARTICLE_API_HOST\":\"https://prd-api.mckinsey.com\",\"SITECORE_FORMS_SERVICES_API_HOST\":\"https://prd-api.mckinsey.com\",\"FEATURE_TOGGLES\":\"{\\\"stack_adapt_pixel\\\": true, \\\"article_seo_schema\\\":true, \\\"remember_me\\\": true, \\\"gql_promo_banner\\\": true, \\\"gql_highlight_bar\\\": true, \\\"gql_ceros_placeholder\\\": true, \\\"gql_two_up_medium\\\": true, \\\"gql_hero_with_partnership_mark\\\": true, \\\"gql_brightcove_gallery\\\": true, \\\"gql_one_up_medium\\\": true, \\\"gql_promo_bar_with_quote\\\": true, \\\"gql_fifty_fifty_hero\\\": true, \\\"gql_enhanched_hero\\\": true, \\\"gql_two_up_small\\\": true, \\\"gql_general_up\\\": true, \\\"gql_full_bleed_hero\\\": true, \\\"passwordless_login_enabled\\\": true, \\\"sso_enabled\\\": true, \\\"article_id\\\": \\\"\\\", \\\"personalisation_enabled\\\":true, \\\"hide_student_sticky_footer\\\":true, \\\"email_domain_validation_enabled\\\":true}\",\"HEADER_SCRIPT_HASH\":\"abcd1234\",\"OKTA_AUTH_CLIENT_ID\":\"0oa8ppb3ypQ8uOI8y697\",\"OKTA_AUTH_ISSUER\":\"https://dotcomidp.mckinsey.com/oauth2/aus2byav0jTElyFDD697/\",\"AUTO_REDIRECTION_DURATION\":\"5\",\"LINKEDIN_IDP\":\"0oaecyj1byxnfrfFk697\",\"APPLE_IDP\":\"0oaeg2lxy6mq4PX5F697\",\"GOOGLE_IDP\":\"0oaeczfkb03XL3E4O697\",\"ALUMNI_BASE_API_URL\":\"https://dev-gateway.intranet.mckinsey.com/:apiKey/v1\",\"ALUMNI_AUTHENTICATE_API_URL\":\"https://dev-ac3-okta-auth.intranet.mckinsey.com/authenticate\",\"ALUMNI_OKTA_URL\":\"\",\"ALUMNI_OKTA_ENABLED\":\"true\",\"GOOGLE_MAP_API_KEY\":\"AIzaSyDqrGDNMDjy9pXHkMf-_Ut33LoC725GSe4\",\"AWS_GATEWAY\":\"https://dev-gateway.mckinsey.com\",\"AWS_API_GATEWAY_ID\":\"o63viscaj4\",\"AWS_PERSONALIZATION_TRACKING_ID\":\"f3f97bc3-4ca7-4960-9e49-0bcff6294ab4\",\"AWS_PERSONALIZATION_CID\":\"recommendations-onw-onw-mck-mck-art-2410-v1-user-ext-web\",\"EVENTS_MODULE_CARDS_COUNT\":\"8\",\"RECOMMENDATIONS_OFFER_ACTIVITY\":\"Article Recommendations\"},\"isFallback\":false,\"dynamicIds\":[70281,73769,76731,98391],\"gssp\":true,\"locale\":\"en\",\"locales\":[\"en\",\"da-DK\"],\"defaultLocale\":\"en\",\"isPreview\":true,\"scriptLoader\":[]}</script><script type=\"text/javascript\" src=\"/1sISTh/L/u/nAoEgpNcfg7J/GaO3tL2mVXLX7b/BVlZblY_cBA/SXAe/KgkXcSUB\"></script><div id=\"floating-ui-root\"></div><script src=\"https://assets.adobedtm.com/b0dfb38aec8a/63974894e9a9/launch-a400cfbb2fd3.min.js?l=1\" data-nscript=\"afterInteractive\"></script><script id=\"data-layer\" data-nscript=\"afterInteractive\">eventDataLayer.pageLoadCompleted()</script><next-route-announcer><p aria-live=\"assertive\" id=\"__next-route-announcer__\" role=\"alert\" style=\"border: 0px; clip: rect(0px, 0px, 0px, 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap; overflow-wrap: normal;\"></p></next-route-announcer></body></html>"
}